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Homology-directed repair (HDR) plays a crucial role in the repair of DNA double-
strand breaks. Defects in genes involved in HDR compromise genome integrity and 
predispose cells to tumorigenesis. The breast tumor suppressor BRCA1 is essential for 
HDR in part through antagonizing the nonhomologous end joining factor 53BP1. The 
ATM kinase is involved in various aspects of DNA damage signaling. Both BRCA1 
and ATM have functions in the early steps of HDR, however their epistatic 
relationship is largely unclear. In this study we address how mutations in BRCA1 
affect its genetic interaction with ATM and 53BP1 in HDR. In a Brca1S1598F mouse 
model carrying a mutation in the phosphoprotein-binding BRCT domain at the C 
terminus, ATM becomes critical to support HDR and this regulation is independent of 
the BRCA1-53BP1 antagonism. Deficiency of ATM leads to synthetic lethality in the 
Brca1S1598F mutant mice associated with severely compromised HDR. On the other 
hand, in a Brca1ex11 mutant expressing the BRCA1 Δ11 splicing isoform lacking the 
central region, whether ATM supports HDR is modulated by the status of 53BP1: 
Only in the absence of 53BP1 does ATM promote HDR. These results suggest that 
mutations in the BRCT domain and the exon 11-encoding region of BRCA1 
differentially affect how ATM kinase participates in HDR. Importantly, while 
normally not essential, ATM could be critical for HDR proficiency in certain contexts 
of BRCA1 deficiency, providing a new perspective for targeting BRCA1 mutant 
tumors.  
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CHAPTER ONE 
INTRODUCTION - THE ROLES OF BRCA1 AND ATM IN  
HOMOLOGY-DIRECTED REPAIR* 
 
DNA molecules in cells are constantly undergoing damage from both endogenous and 
exogenous sources that generate a variety of DNA lesions (1, 2). Among them, a 
double-strand break (DSB) is one of the most cytotoxic types of DNA damage that 
poses a significant threat to genome integrity. DSBs are repaired by two major 
pathways in mammalian cells: homology-directed repair (HDR), also known as 
homologous recombination, and nonhomologous end joining (NHEJ) (3). HDR is 
considered a relatively error-free repair mechanism, and defects in HDR subject the 
cells to the utilization of more error-prone repair such as NHEJ that predispose cells to 
genome instability and tumorigenesis. 
 A critical step initiating HDR is the resection of DNA ends to generate 3’ 
single-stranded DNA (ssDNA) for recombination (4). Evidence suggests that this 
process occurs through a two-step mechanism (5, 6). The initial stage of limited 
resection is mediated by the MRE11 endonuclease activity of the MRE11-RAD50-
NBS1 (MRN) complex stimulated by the co-factor CtIP. This is followed by an 
extensive, bi-directional resection involving the 3’-5’ exonuclease activity of MRE11 
together with the 5’-3’ exonuclease activity of EXO1 and DNA2. The ssDNA 
overhang is then bound by the recombination protein RAD51, which displaces RPA 
and promotes strand exchange with a homologous template, typically the sister 
chromatids during S/G2 phases of the cell cycle, thus allowing for the faithful 
restoration of wild-type sequence (Figure 1.1). In canonical NHEJ (C-NHEJ), DNA  																																																								*	Chen CC, Feng W, et al. (2018) Homology-Directed Repair and the Role of 
BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer. Annu. Rev. 
Cancer Biol. 2:313–336. (Co-first authors) 
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Figure 1.1 Homology-directed repair (HDR) and other pathways for the repair of 
double-strand breaks (DSBs).  
HDR is a major pathway for the error-free repair of DSBs in S/G2 phases. An early 
determinant of repair pathway choice is end resection that generates 3’ single strands. 
This is regulated by BRCA1 in competition with 53BP1 and can occur through an 
initial phase to produce short 3’ overhangs (<100 base pairs) and a more extensive 
phase to produce longer 3’ overhangs (hundreds of base pairs), as shown in yeast. 
BRCA1 also promotes the later steps of HDR via interaction with PALB2, which in 
turn recruits BRCA2. The defining step of HDR is controlled by BRCA2 that 
promotes the formation of RAD51 filaments on the 3’ single strands, followed by 
strand invasion into a homologous DNA, typically the sister chromatid, priming repair 
DNA synthesis. DSBs can also be repaired by error-prone repair pathways. Canonical 
nonhomologous end joining (NHEJ) can occur during any cell cycle phase and is 
considered the other major DSB repair pathway. In NHEJ, DNA ends are protected 
from end resection, but often undergo some processing before joining that results in 
small insertions/deletions. Initial and extensive end resection also provides 
intermediates for two other DSB repair pathways, alternative NHEJ involving 
microhomology, also termed microhomology-mediated end joining (MMEJ), and 
single-strand annealing (SSA) involving longer stretches of homology. Consistent 
with their involvement in different steps of HDR, BRCA1 promotes HDR and SSA, 
whereas BRCA2 promotes HDR and suppresses SSA. 
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ends are bound by the Ku70/80 heterodimer, which then recruits the DNA-PK 
catalytic subunit (DNA-PKcs) forming the DNA-PK holoenzyme, and joined directly 
by the XRCC4-DNA Ligase IV complex (7). This process is considered to be active 
throughout the cell cycle and is frequently accompanied by mutagenic insertions or 
deletions at the junctions due to the activity of polymerases or nucleases. DSBs can 
also be repaired by other minor pathways including alternative end joining (alt-EJ) and 
single-strand annealing (SSA), both are considered error-prone mechanisms (8, 9) 
(Figure 1.1). Alt-EJ can occur in the absence of C-NHEJ machinery and involves 
noncanonical factors such as DNA Ligase III for the joining activity. Some end 
joining events could also rely on a few base pairs of microhomologous sequence 
exposed on short stretches of ssDNA following limited resection, hence termed 
microhomology-mediated end joining (MMEJ). More extensive resection could reveal 
longer stretches of homology on both ends of broken DNA that promote the annealing 
of each other via SSA. This process is facilitated by RAD52 and the protruding 3’ 
flaps are then removed, leading to the deletion of sequence within the two homologies.  
 
The roles of breast tumor suppressor BRCA1 in HDR 
The BRCA1 protein is a key player in HDR and an important suppressor of tumors, in 
particular hereditary breast and ovarian cancers. Complete loss of BRCA1 leads to 
early embryonic lethality in mouse models due to the requirement of HDR proficiency 
for embryo development, whereas hypomorphic mutations of BRCA1 in mice can be 
viable but confer genome instability and tumor predisposition (10). Human carriers 
heterozygous for BRCA1 mutations show a significant increase in cancer risks, in 
particular those of the breast (~30-fold higher risk at ages 30-39 then decreasing with 
age) and ovarian cancers (11, 12). Loss of heterozygosity on the wild-type allele is 
frequently observed in breast tumors from carries with deleterious BRCA1 mutations 
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(13). The recent discovery of a patient with biallelic BRCA1 mutations has led to the 
classification of BRCA1 as a Fanconi anemia susceptibility gene (FANCS) (14). 
 BRCA1 participates in both early and later steps of HDR: Following DSB 
formation, BRCA1 is involved in counteracting the NHEJ factor 53BP1 to facilitate 
DNA end resection (see below), an early step in HDR. BRCA1 also interacts with the 
PALB2 protein (15, 16), which in turn recruits BRCA2 to facilitate RAD51 filament 
formation, a later step in HDR. Patient-derived mutations of BRCA1 that impair HDR 
typically also reduce SSA, another DSB repair pathway that requires end resection 
(17, 18). The exceptions are missense mutations in the coiled-coil domain that 
specifically disrupt BRCA1 interaction with PALB2 (Figure 1.2), which show reduced 
HDR but increased SSA, similar to BRCA2 deficiency (17, 18).  
Mutations of BRCA1 in familial breast cancers are frequently located at the 
evolutionally conserved N-terminal RING and C-terminal BRCT domains, such as the 
founder mutations 185delAG and 5382insC, respectively (19, 20) (Figure 1.2). The 
interaction of the RING domain with the BARD1 protein is important for tumor 
suppression and HDR activity (21, 22), whereas the E3 ubiquitin ligase activity of 
BRCA1 itself is dispensable for these processes but has a role in other functions such 
as spermatogenesis (23). The BRCT domain is also critical for tumor suppression and 
other repair functions of BRCA1, particularly in the regulation of chromatin 
localization and HDR (23, 24). The BRCT domain interacts with a number of 
phosphoproteins containing a pSer-X-X-Phe motif, namely Abraxas, BRIP1 (also 
called BACH1), and CtIP, leading to the mutually exclusive formation of the BRCA1-
A, -B, and -C complexes, respectively (25). The components of the BRCA1-A 
complex, namely Abraxas and RAP80, help localize BRCA1 to the ubiquitylated 
chromatin modified by RNF8 E3 ubiquitin ligase (26-29). Loss of Abraxas or RAP80 
increases genome instability and tumor incidence in mice (30, 31), but how HDR is 
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Figure 1.2 Domain structure of the BRCA1 protein. 
BRCA1 is composed of an N-terminal RING E3 ubiquitin ligase domain that interacts 
with the RING domain of its binding partner BARD1; an exon 11-encoding central 
region containing nuclear localization signals (NLSs) and other activities (e.g., 
interaction with DNA and RAD51 protein); a coiled-coil (CC) domain for PALB2 
binding, with an overlapping SQ cluster targeted by the ATM kinase; and tandem 
BRCT repeats at the C terminus for interaction with phosphoproteins. The 
approximate locations of mapped ATM phosphorylation sites are marked by asterisks: 
A few of them are located in the exon 11-encoding region whereas the rest are located 
at or adjacent to the CC domain (Cortez et al., 1999; Matsuoka et al., 2007). At least 4 
ATM target sites are conserved in mice that are equivalent to human S1189 (in exon 
11) and S1387/S1466/S1524 (around CC); note that S1189 is a SP motif which is 
different from the canonical ATM target site. Domain positions are based on 
annotations in the UniProtKB database (http://www.uniprot.org/). aa: amino acids. 
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affected by the loss of the BRCA1-A complex is controversial and several studies 
show that end resection is actually increased leading to excessive end processing (28, 
32, 33). The significance of the BRCA1-C complex in HDR is also elusive, but some 
evidence suggests that the interaction of CtIP with BRCA1 can facilitate CtIP-
mediated resection and the loss of it confers a moderate sensitivity to topoisomerase 
inhibitors in cells (34-38). These studies point out a possible role of BRCA1 in fine-
tuning the extent of end resection through the formation of distinct complexes via its 
BRCT domain.  
 
Antagonism of BRCA1 and 53BP1 in DSB repair pathway choice 
The repair pathway choice of HDR versus NHEJ is regulated in a cell cycle-dependent 
manner through a mutual antagonism between BRCA1 and 53BP1 (39, 40). The 
53BP1 protein is recruited to DSB sites through association with histone markers such 
as the dimethylated histone H4K20 and ubiquitylated H2AK15 (41-43) (Figure 1.3). 
53BP1 is not a core component of the end-joining complex but contributes to NHEJ in 
certain contexts. For example, 53BP1 has important roles in lymphocyte development 
by promoting the class switching recombination (CSR) of immunoglobulin heavy 
chains and the synapsis of long-range V(D)J recombination for T cell receptors (44-
46). 53BP1 also regulates chromatin mobility that contributes to the end-to-end fusion 
of uncapped telomeres (47). In G1 phase, 53BP1 suppresses end resection in an ATM-
dependent manner, thus allowing for efficient NHEJ. Deficiency of 53BP1 abrogates 
the protection of DNA ends and predisposes mice to lymphoma particularly in the 
p53-deficient condition due to the increased levels of end processing and oncogenic 
translocations (46, 48-50). On the other hand, in S/G2 phases, BRCA1 is required to 
counteract 53BP1 in order to promote end resection. This ensures that HDR occurs 
when sister chromatids are available to template HDR. Importantly, loss of 53BP1  
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Figure 1.3 Domain structure of the 53BP1 protein. 
53BP1 is composed of an N-terminal 28 SQ/TQ cluster that interacts with RIF1 and 
PTIP (via the 8 sites at the very N terminus) in an ATM-dependent manner; an 
oligomerization domain (OD) involved in damage foci formation; a	glycine arginine 
rich (GAR) motif; a Tudor domain that binds to dimethylated H4K20 and is important 
for 53BP1’s functions in resection inhibition and class switching; a ubiquitination-
dependent recruitment (UDR) motif that binds to ubiquitylated H2AK15; a nuclear 
localization signal (NLS); and C-terminal tandem BRCT repeats for interaction with 
proteins such as p53. Domain positions are based on annotations in the UniProtKB 
database (http://www.uniprot.org/). aa: amino acids. 
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rescues the HDR defects and lethality of BRCA1- but not BRCA2-deficient cells (51-
53). Thus, the role of BRCA1 in antagonizing 53BP1 is likely more pivotal than a 
direct role for BRCA1 in end resection per se. Besides the BRCA1-53BP1 
antagonism, other mechanisms also contribute to the cell cycle-dependent regulation 
of HDR. For example, phosphorylation of CtIP by CDK in S/G2 phases is crucial for 
its resection function in cooperation with the MRE11 (54-56). The ubiquitination of 
PALB2 by the E3 ubiquitin ligase CRL3-KEAP1 in G1 phase suppresses the BRCA1-
PALB2 interaction and recombination (57). Notably, depletion of 53BP1 and KEAP1 
together with the expression of the CtIPT847E phosphomimetic mutant allow HDR to 
occur in G1 cells (57), highlighting how multiple factors coordinate to restrict the 
untimely activation of HDR outside S/G2 phases. 
Given the additional, later role for BRCA1 in HDR, it seems surprising that 
53BP1 loss can fully restore HDR in BRCA1-deficient settings. Possibly, 53BP1 loss 
creates more resected ssDNA that mitigates the requirement for BRCA1 in mediating 
PALB2 and BRCA2 recruitment for RAD51 filament formation (58, 59). 
Alternatively, additional factors such as ATM/ATR-mediated phosphorylation may 
contribute to the regulation of PALB2 in this context (60). Importantly, some aspects 
of BRCA1 function cannot be rescued by 53BP1 loss, such as interstrand crosslink 
repair and replication fork protection (61-63), suggesting a distinct role of BRCA1 in 
repairing stalled fork lesions.  
ATM-mediated phosphorylation of 53BP1 is required for the interaction of 
several 53BP1-binding proteins, namely RIF1 and PTIP, to suppress end resection in 
G1 phase (34, 64-69). The interaction with PTIP depends on the phosphorylation of 
the 8 most N-terminal SQ/TQ sites on 53BP1, whereas RIF1 binding is partially 
dependent on the 7 SQ/TQ sites immediately downstream of the 8 PTIP-recognizing 
residues and is abrogated when all 28 SQ/TQ sites at the N terminus of 53BP1 are 
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mutated (Figure 1.3). Loss of RIF1 in mice leads to CSR defects and hyper-resection 
at DSBs at the immunoglobulin heavy chain genes and at uncapped telomeres, similar 
to the phenotypes of 53BP1-deficient mice. However, RIF1 loss does not rescue the 
HDR defect of BRCA1-deficient cells to the same extent as 53BP1 loss. By contrast, 
PTIP appears to a more prominent role than RIF1 in counteracting BRCA1. PTIP 
deficiency attenuates the fusion of uncapped telomeres but does not affect the NHEJ 
aspect of CSR. Notably, loss of PTIP in BRCA1-deficient cells almost completely 
rescues HDR and suppresses chromosome aberrations following treatment with 
poly(ADP-ribose) polymerase (PARP) inhibitors (see below). These observations 
illustrate how 53BP1 regulates repair pathway choice through distinct interacting 
proteins in different contexts.  
 The mechanism by which BRCA1 counteracts 53BP1 to allow for end 
resection is not well understood and is likely to be complex. CtIP, which interacts with 
BRCA1, is a critical resection factor (70), such that 53BP1 loss fails to rescue the 
lethality of CtIP-deficient mice (71). It is possible that BRCA1 stimulates the end 
resection machinery, including CtIP, to have limited generation of ssDNA that in turn 
displaces NHEJ components. For example, activities of the resection factors MRE11 
and CtIP can limit the accumulation of Ku at DSB ends (72, 73). However, depletion 
of Ku cannot rescue cellular lethality associated with BRCA1 deficiency in mice, 
despite a reduction in chromosome aberrations (62). Given that Ku binds only to DNA 
ends whereas 53BP1 binds modified histones surrounding the DSB site, the presence 
of ssDNA alone may not be sufficient to abolish 53BP1 action. Consistent with the 
notion, the transition from a 53BP1 block of resection to BRCA1-mediated HDR can 
be facilitated by several chromatin modifying proteins (e.g., histone acetyltransferases 
TIP60/KAT5 and MOF/KAT8) or chromatin remodelers (e.g., SMARCAD1 and 
CSB) (74-77). BRCA1 may also actively disrupt the function of the 53BP1 complex to 
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abrogate the blockade of HDR. For example, BRCA1 disrupts the interaction of 
53BP1 and RIF1 in S/G2 phases through promoting the dephosphorylation of 53BP1 
by the PP4C phosphatase and targeting RIF1 by an E3 ubiquitin ligase UHRF1 (78, 
79). BRCA1 also induces an active repositioning of 53BP1 as observed in the 
exclusion of 53BP1 signal from the core of DNA damage foci in S/G2 phases (80, 81).  
 
Loss of end resection suppressors confers resistance to PARP inhibitor  
Studies have demonstrated that HDR-deficient cells are extremely sensitive to the 
inhibition of PARP (82, 83). The activity of PARP is involved in the efficient repair of 
single-strand breaks, and PARP inhibition (PARPi) results in the accumulation of 
DSBs converted from single-strand breaks during replication and the trapping of the 
inactive PARP1/2 enzymes on DNA that require HDR machinery to resolve (84-86). 
Chromosome aberrations arising from toxic NHEJ events also contribute to the 
sensitivity to PARPi in HDR-deficient human cells (87). These studies have led to the 
concept of synthetic lethality that targets tumors defective in BRCA1/2 or other HDR 
factors with PARPi (88).  
Despite the effective response to PARPi in HDR-deficient tumors, the 
development of resistance has been a crucial problem in the clinic (88). Elevated 
expression of membrane transporters can promote drug efflux. Reduced levels of 
PARP1/2 enzyme expression or activity can attenuate the pharmacological actions of 
PARPi. The most common mechanism of acquired resistance is through reversions in 
the BRCA1/2 genes that recover wild-type sequence or new frame-restoring isoforms 
regaining some levels of HDR proficiency. Recent studies demonstrate that BRCA1 
mutant mouse and human cells can bypass nonsense mutations within the N-terminal 
RING domain by expressing a RING-less truncated protein that is not proficient in 
tumor suppression but is partially competent in HDR, leading to poor therapeutic 
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responses (89, 90). Another resistance mechanism related to BRCA1 deficiency is the 
restoration of HDR through the loss of resection suppressors such as 53BP1. 
Constitutional loss of 53BP1 reduces the spontaneous mammary tumorigenesis in 
BRCA1-deficient mice (52, 53), consistent with the notion that HDR proficiency 
suppresses tumors. However, BRCA1-deficient mammary tumors arising in 53BP1 
wild-type mice can acquire PARPi resistance through somatic loss of 53BP1 (91). 
Furthermore, selection of PARPi-resistant BRCA1-mutated tumor cells is also 
associated with reduced 53BP1 expression (91, 92). Notably, however, because 
BRCA1 has distinct roles in interstrand crosslink repair (63), 53BP1 loss does not lead 
to cross-resistance to platinum drugs (62).  
Loss of other proteins that affect the levels of end-resected DNA, such as 
REV7 and HELB, are similarly found to confer PARPi resistance (87, 93-96). These 
proteins could operate in the same pathway as 53BP1 or in independent steps, such as 
in the extensive end resection. Notably, given that ATM contributes to HDR in the 
BRCA1-53BP1 double mutant cells (52), evidence suggests that the HDR-restored 
BRCA1-deficient tumor cells can be re-sensitized to PARPi by treatments with ATM 
kinase inhibitors (93, 94). ATR kinase also has a role in bypassing the requirement for 
BRCA1 for HDR in PARPi-resistant cells by promoting RAD51 recruitment to 
damage sites (97). Given the use of bioavailable inhibitors of ATM or ATR in 
combination with genotoxic therapies in mouse tumor models (98-100), the combined 
treatments with PARPi and ATM/ATR inhibitors have the potential for treating 
BRCA1-deficient tumors. 
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Figure 1.4 Domain structure of the ATM kinase. 
ATM kinase is comprised an N-terminal helical solenoid region formed by 
consecutive HEAT repeats; a FAT domain involved in the trans-inhibition of ATM 
kinase activity in the dimerized form; a PI3K-related Ser/Thr kinase domain that 
preferentially recognizes SQ or TQ motif on substrates; and a C-terminal FAT 
(FATC) domain that interacts with Tip60 histone acetyltransferase contributing to 
ATM activation. The activity of ATM is regulated by three major autophosphorylation 
sites S367/S1893/S1981 as well as a Tip60-mediated acetylation site on K3016. 
Domain positions are based on annotations in the UniProtKB database 
(http://www.uniprot.org/). aa: amino acids. 
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The roles of ATM kinase in HDR  
The ATM kinase has critical roles in the DNA damage response and checkpoint 
regulation following DSBs (101). ATM is a Ser/Thr kinase belonging to the PI3K-
related kinase family (Figure 1.4), whose members also include ATR and DNA-PKcs 
which are also important for the DNA damage response. Biallelic ATM mutations 
result in the neurodegenerative syndrome ataxia-telangiectasia (A-T), which is highly 
associated with tumor predisposition, primarily lymphoid tumors during childhood 
whose incidence correlates with the absence of any residual ATM kinase activity 
(102-104). A-T patients who survive to adulthood are also prone to solid tumors, in 
particular those of the breast (~30-fold increased risk) (102). Monoallelic ATM 
mutations in carriers also lead to a moderate but significant increase in breast cancer 
risk (~2-fold), making ATM a putative breast cancer susceptibility gene (105-107). 
Evidence also suggests mice heterozygous for an Atm nullizygous allele could 
promote mammary tumorigenesis under certain backgrounds (108-110). The majority 
of ATM mutations associated with A-T are truncations, however, studies suggest that 
those associated with cancers tend to be missense mutations, frequently in the kinase 
domain of ATM (103, 111, 112). Inhibition of ATM kinase activity is shown to 
promote the transformation of normal human mammary epithelial cells (113), in 
agreement with its association with breast cancer suppression.  
ATM kinase is activated in response to multiple conditions including DSBs, 
chromatin perturbation, and oxidative stress (114). ATM is normally maintained as 
catalytic inactive dimers in cells and is activated through a monomerization process 
following DSBs (115, 116). Studies in vitro suggest that the monomerization of ATM 
is facilitated by the MRN complex in the presence of DNA ends that result in the 
phosphorylation of ATM substrates (117, 118). Activation of ATM upon oxidative 
stress involves crosslinked dimers formed via oxidized disulfide bonds and is 
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independent of the MRN-mediated monomerization (119). In human cells undergoing 
DNA damage, autophosphorylation of ATM on S1981 is shown to unmask the trans-
inhibition of its kinase domain in the dimer, which is critical for the monomerization 
and activation of ATM (115, 120). However, other reports suggest that 
autophosphorylation is mainly responsible for the retention of active ATM at the 
breaks but not the initial recruitment (121), and in vitro studies using human ATM 
also suggest that autophosphorylation is not required for the activation process or 
substrate phosphorylation (117). In mice, mutation on the residue equivalent to human 
S1981 alone or together with mutations on two additional autophosphorylation sites 
does not affect the functions of ATM in the DNA damage response (122, 123), raising 
the possibility of species difference in the regulatory mechanisms of ATM.   
In addition to its roles in checkpoint signaling, ATM activity is also implicated 
in DSB repair mechanisms. ATM functions in NHEJ in part through maintaining the 
fidelity of the joining process particularly during distant joining, which is important 
for the V(D)J recombination and CSR in B and T lymphocytes (124-127). Deficiency 
of ATM leads to aberrant repair of RAG-induced DSBs and chromosomal 
translocations that, together with the lack of an ATM-mediated G1/S checkpoint, 
promote the development of lymphoid tumors both in A-T patients and mouse models 
(128-132). On the other hand, the association of ATM deficiency with breast cancer 
risk and the sensitivity of ATM-deficient cells to PARPi (87, 133-135) raise the 
question of a potential role for ATM in HDR. Loss of ATM has been shown to impact 
HDR in some contexts but not in others depending on the cell types, nature of DNA 
breaks, or the HDR assays examined (133, 136-141). This may be in part due to the 
redundancy of substrate phosphorylation by related kinases including ATR and DNA-
PKcs (142) or simply a context-dependent requirement for ATM. However, a number 
of ATM targets have been clearly implicated in the HDR machinery. For example, 
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phosphorylation of CtIP by CDK and ATM on a number of residues is critical for end 
resection and HDR (56, 143-145). ATM has also been shown to phosphorylate 
MRE11 and EXO1 to modulate the extent of end resection for optimal recombination 
activity (146, 147). Loss of ATM or inhibition of its activity reduces the levels of 
ssDNA generated from resection as measured by nuclear RPA foci or PCR-based 
resection assays (140, 148-151). ATM has also been shown to function in later steps 
of HDR (60, 152). Another aspect of ATM function is to promote heterochromatin 
relaxation by phosphorylating and inactivating KAP1 to allow for the access of the 
repair machinery (153).  
Recent studies in mice have shown that expression of a kinase-dead ATM 
protein leads to embryonic lethality in mice and a more severe HDR defect than loss 
of the ATM protein itself (112, 154, 155). In particular, kinase-dead Atm mutant 
mouse cells are more sensitive to a topoisomerase I inhibitor than Atm-null cells in 
part due to the inability to remove the DNA adducts, providing implications for 
targeting cancers carrying kinase-inactivating mutations of ATM (112). The kinase-
dead ATM protein can still localize to the sites of DNA damage, however, cells 
heterozygous for the kinase-dead Atm allele do not have observable repair defects 
(154, 155). It is possible that the kinase-dead ATM protein is deficient in certain self-
regulatory mechanisms, e.g., dissociation from breaks, thus leading to more prominent 
interference with DSB repair in the absence of wild-type ATM. 
 
Summary 
 The epistatic relationships between ATM, BRCA1, and 53BP1 in the early 
steps of DSB repair are not fully understood. Although the interaction of 53BP1 with 
RIF1 or PTIP in G1 phase depends on ATM, inhibition of ATM activity in 53BP1-
deficient lymphocytes reduces the hyper-resection of RAG-induced DSBs and also 
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partially rescues CSR defects (48, 156-158), suggesting ATM-mediated end resection 
can occur in G1 phase following 53BP1 loss. On the other hand, ATM also 
phosphorylates BRCA1 following DNA damage at multiple sites that promote the 
functions of BRCA1 in checkpoint regulation (159-162). Although the significance of 
these phosphorylations on BRCA1-mediated HDR is not clear, combined mutations of 
three phosphorylation sites (human residues S1423/S1387/S1524) abrogate the ability 
of BRCA1 to support cellular viability (163). Given that ATM is a master regulator at 
DSB sites, it would be important to determine if ATM has active roles in regulating 
the choice of DSB repair pathways and how this could affect the therapeutic responses 
or resistance mechanisms in HDR-deficient tumors. 
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CHAPTER TWO 
ATM LOSS LEADS TO SYNTHETIC LETHALITY IN BRCA1 BRCT 
MUTANT MICE ASSOCIATED WITH EXACERBATED DEFECTS IN 
HOMOLOGY-DIRECTED REPAIR* 
 
Abstract 
BRCA1 is essential for homology-directed repair (HDR) of DNA double-strand 
breaks in part through antagonism of the nonhomologous end-joining factor 53BP1. 
The ATM kinase is involved in various aspects of DNA damage signaling and repair, 
but how ATM participates in HDR and genetically interacts with BRCA1 in this 
process is unclear. To investigate this question, we used the Brca1S1598F mouse model 
carrying a mutation in the BRCT domain of BRCA1. Whereas ATM loss leads to a 
mild HDR defect in adult somatic cells, we find that ATM inhibition leads to severely 
reduced HDR in Brca1S1598F cells. Consistent with a critical role for ATM in HDR in 
this background, loss of ATM leads to synthetic lethality of Brca1S1598F mice. While 
both ATM and BRCA1 promote end resection, which can be regulated by 53BP1, 
53bp1 deletion does not rescue the HDR defects of Atm mutant cells, in contrast to 
Brca1 mutant cells. These results demonstrate that ATM has a role in HDR 
independent of the BRCA1-53BP1 antagonism and that its HDR function can become 
critical in certain contexts.  
 
Introduction 
A DNA double-strand break (DSB) is one of the most cytotoxic types of DNA damage 
and poses a significant threat to genome integrity. Two major DSB repair pathways 																																																								*	Chen CC, et al. (2013) ATM loss leads to synthetic lethality in BRCA1 BRCT 
mutant mice associated with exacerbated defects in homology-directed repair Proc. 
Natl. Acad. Sci. U. S. A. 114(29):7665-7670. 
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exist in mammalian cells: homology-directed repair (HDR) and non-homologous end 
joining (NHEJ) (1, 2). In NHEJ, DNA ends are minimally processed before rejoining. 
By contrast, HDR initiates with resection of DNA ends to generate single-stranded 
DNA for RAD51-mediated strand invasion of a homologous template. HDR is 
considered a relatively error-free repair pathway, such that defects in HDR result in 
the use of more error-prone repair mechanisms that predispose cells to genome 
instability and tumorigenesis or cell death. 
An essential HDR factor is the breast tumor suppressor BRCA1, which 
promotes the initial end resection step of HDR, as well as later steps of recombination 
(1, 3). HDR defects in BRCA1-deficient cells can be suppressed by loss of 53BP1, an 
NHEJ protein that impedes end resection (4-6). BRCA1 and 53BP1 operate 
antagonistically at different cell cycle phases: 53BP1 and its interacting proteins 
counteract BRCA1 in G1 phase to limit end resection; by contrast, BRCA1 suppresses 
53BP1 function in S/G2 phases to promote HDR (3, 7). In addition to antagonizing 
53BP1, BRCA1 binds to the resection factor CtIP and facilitates its activity, although 
the mechanisms merit further investigation (8-11) 
 ATM kinase is the master regulator of the DNA damage signaling and repair 
machinery in response to DSBs, and a suppressor of lymphoid and mammary tumors 
(12, 13). In repair, ATM is implicated in various aspects of NHEJ, e.g., in maintaining 
the fidelity of the joining process (14, 15). ATM-mediated phosphorylation is required 
for the proper functions of 53BP1 in NHEJ (3, 7) and for the destabilization of 
BRCA1-PALB2 complex to prevent HDR in G1 phase (16). Conversely, ATM is also 
proposed to participate in HDR (17, 18), e.g., by phosphorylating CtIP in cooperation 
with cyclin-dependent kinase (CDK) to stimulate end resection in S/G2 phases (19-
23). However, several studies have shown that ATM is not essential for HDR in some 
contexts, e.g., mouse embryonic stem (ES) cells (24-27). Further, unlike the severe 
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phenotypes of mice deficient in core HDR factors such as BRCA1 (28), Atm 
nullizygous mice are viable (29, 30). Therefore, it remains an open question whether 
ATM plays a significant role in HDR. 
 In this study, we examine the genetic interactions between ATM, BRCA1, and 
53BP1 in mice using a hypomorphic mutant, Brca1S1598F (Brca1SF), carrying a breast 
cancer-derived mutation in the BRCT domain that disrupts the hydrogen bond 
interaction with the phosphate group of incoming phosphoproteins (31). We present 
evidence that ATM is critical for the residual HDR in Brca1SF cells, and that loss of 
ATM in Brca1SF mice leads to synthetic lethality, consistent with the embryonic 
lethality of mouse mutants with severe HDR defects. Interestingly, unlike in the 
Brca1SF mutant, the resection and HDR defects in the Atm mutant cannot be rescued 
by 53bp1 deletion. These genetic analyses indicate that ATM has a role in HDR 
independent of the BRCA1-53BP1 antagonism and, while normally not essential for 
HDR, this role becomes critical when certain functions of BRCA1 are compromised.  
 
Results 
ATM inhibition reduces HDR in Brca1SF embryonic stem cells.  
Since BRCA1 and ATM have both been implicated in DNA end resection, the first 
step of HDR, we investigated the genetic interaction of the two proteins. While 
complete loss of BRCA1 leads to cell lethality, mice carrying the Brca1S1598F 
hypomorphic allele are viable (31) (Figure 2.1A). HDR was substantially reduced in 
the mouse Brca1SF/SF ES cells, as demonstrated using the direct repeat (DR)-GFP 
reporter assay (>5-fold) (31) (Figure 2.1B). By contrast, HDR levels were not 
significantly reduced in the Atm-/- cells (Figure 2.1B), as previously reported (25-27), 
indicating that ATM is not required for HDR in these cells. However, we observed 
that HDR was reduced at an earlier time point (24 versus 48 hours after transfection),  
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Figure 2.1 HDR is defective in Brca1SF/SF whereas only delayed in Atm-/- ES cells. 
A. Mouse BRCA1 S1598F (SF) protein carries a breast cancer-derived point mutation 
in the BRCT domain that interrupts the interaction with phosphoproteins. 
B. The DR-GFP reporter consists of two copies of mutant GFP genes. A DSB 
introduced by I-SceI endonuclease in SceGFP can be repaired by HDR using iGFP as 
a template and restore a functional GFP+ gene. HDR is substantially reduced in 
Brca1SF/SF ES cells. HDR in Atm-/- ES cells has no significant difference from WT 
cells, however a ~1.6-fold reduction is seen at earlier time point (24 hr post 
transfection of an I-SceI expression vector). All error bars in the figures of this chapter 
represent one standard deviation from the mean. (n≥3) 
C. To clarify the impact of ATM loss on HDR, three independent Pim1Drgfp targeted 
clones of WT and Atm-/- ES cells, respectively, are examined. The average HDR of the 
three clones is reduced by ~1.5-fold in Atm-/- ES cells at 24 hr (left) but not 48 hr 
(middle) after transfection of an I-SceI expression vector, confirming a delay in HDR 
(WT n=12; Atm-/- n=13 transfections combined). The levels of HDR in individual 
clones are summarized (right) and are consistent with the notion above. J1 clone 8 and 
Atm-/- clone 1 are used for the rest of ES cell experiments in Chapter 2 and 3.  
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such that Atm-/- ES cells showed a delay in HDR, but eventually reached wild-type 
levels. We further analyzed the average levels of HDR of three independent clones 
integrated with the DR-GFP reporter for WT J1 and Atm-/- ES cells, respectively, and 
the comparison between them supported the notion of delayed HDR response in Atm-/- 
ES cells (Figure 2.1C). 
To examine the interaction between ATM and the BRCA1 mutant, ES cells 
were treated with an ATM inhibitor (ATMi, KU-55933). ATMi treatment reduced 
HDR in both WT and Brca1SF/SF cells; the reduction was greater in Brca1SF/SF cells, 
leading to an overall 19-fold reduction in HDR compared to DMSO-treated WT cells 
(Figure 2.2A). These differences were not related to changes in cell cycle distribution 
(Figure 2.2B). Thus, ATM kinase activity supports HDR in Brca1SF/SF cells.  
 We also examined the response of these ES cell lines to olaparib, a poly(ADP-
ribose) polymerase inhibitor (PARPi), treatment of which is synthetically lethal with 
HDR deficiency (32). Transient olaparib exposure had little effect on WT ES cells at 
the doses tested, but decreased colony formation of both mutants (Figure 2.2 C and D). 
Interestingly, Atm-/- ES cells (IC50: 13.8 nM) showed a similar sensitivity as Brca1SF/SF 
cells (IC50: 14.5 nM), despite only a kinetic delay in HDR in the DR-GFP assay, 
suggesting additional repair deficiencies such as processing of DNA ends at trapped 
PARP complexes (33). Notably, ATM inhibition in Brca1SF/SF cells further increased 
the sensitivity of these cells to olaparib in colony formation assays (Figure 2.2 C and 
D; IC50 with ATMi: 3.9 nM), consistent with the exacerbated HDR defect (Figure 
2.2A).  
 The mouse Brca1SF mutation encodes a protein that corresponds to the familial 
breast cancer mutation S1655F which disrupts the interaction of the BRCT domain 
with a number of phosphoproteins, including the resection factor CtIP (34). Previous 
studies have shown that phosphorylation of human CtIP at residue S327 (S326 in  
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Figure 2.2 ATM inhibition further reduces HDR in Brca1SF/SF ES cells. 
A. Treatment with ATMi (3 µM, 24 hr) suppresses HDR to a greater extent in 
Brca1SF/SF than in WT ES cells. (n=5) 
B. Treatment with ATMi (3 µM, 24 hr) does not significantly affect cell cycle 
distribution of ES cells. (n=3) 
C. ES cells are transiently treated with different doses of olaparib for 2 days with or 
without continuous ATMi treatment (3 µM). IC50 of olaparib treatment (2-day pulse) 
with/without ATMi: Atm-/-, 13.8/9.8 nM; Brca1SF/SF, 14.5/3.9 nM.  
D. Brca1SF/SF ES cells show a further reduction in colony number upon the combined 
treatment with olaparib (2-day) and ATMi (continuous). The fold is relative to the 
colony number of DMSO treatment for each genotype. The colony reduction in 
ATMi-treated Atm-/- cells is likely due to off-target effects of the ATMi. (n=3) 
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Figure 2.3 HDR in CtipS326A mutant does not recapitulate Brca1SF in the response 
to ATMi. 
A. HDR in CtipS326A/- ES cells, which express a mutant CtIP deficient in binding 
BRCA1, is not significantly different from Ctip+/- control cells. Two independent 
clones are examined for each genotype. (n≥3 for each clone) 
B. ATMi treatment in CtipS326A/- ES cells does not reduce HDR to a greater extent than 
in the Ctip+/- cells. (n≥3) 
C. ATMi-treated CtipS326A/- ES cells are slightly more sensitive to olaparib compared 
to Ctip+/- cells in colony assay, however the level is not comparable to the 
hypersensitivity in Brca1SF/SF cells. * p<0.05 vs. Ctip+/- (n=4) 
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mouse) mediates its interaction with BRCA1 (35). CtIP phosphorylation at this residue 
is not essential for end resection but can stimulate the process (9).  
 We asked whether mouse cells expressing CtIP S326A, which is deficient in 
binding BRCA1 (8), recapitulate Brca1SF mutant phenotypes and have a similar 
dependence on ATM for HDR. Unlike Brca1SF/SF ES cells, CtipS326A/- ES cells showed 
no significant reduction in HDR, as reported previously (8) (Figure 2.3A), and ATMi 
treatment reduced HDR in CtipS326A/- cells no more than that in Ctip+/- cells (Figure 
2.3B). Further, CtipS326A/- cells showed only a mild sensitivity to olaparib compared to 
Brca1SF/SF cells and, while inhibition of ATM in the olaparib-treated CtipS326A/- cells 
reduced survival more than that in Ctip+/- cells, it was not equivalent to the extreme 
hypersensitivity of the similarly treated Brca1SF/SF cells (Figure 2.3C). Thus, 
disruption of the interaction of CtIP with BRCA1 does not recapitulate the phenotype 
of Brca1SF/SF cells, including the degree of dependence on ATM for HDR. 
Accordingly, the CtipS326A mutant mice also lack the tumor-prone phenotype observed 
in the Brca1SF mutant mice (8, 31). This suggests that loss of interaction of the BRCT 
domain with other or additional factors may be responsible for the phenotype of 
Brca1SF mutant. 
Brca1SF mutation is synthetically lethal with Atm nullizygosity.  
Brca1Δ11/Δ11 mice that express the exon 10-12 spliced product of BRCA1 with an 
intact BRCT domain die during embryogenesis (36), but loss of ATM or CHK2 
rescues the embryonic lethality (37). Presumably, unrepaired DNA damage triggers a 
DNA damage response through ATM-CHK2 that confers a survival disadvantage to 
Brca1Δ11/Δ11 embryos. Brca1SF/SF mice show a less penetrant phenotype than 
Brca1Δ11/Δ11 mice: Brca1SF/SF mice can be recovered, but they were observed at about 
half the expected Mendelian frequency at weaning (Figure 2.4A). To determine if the 
reduced survival of Brca1SF/SF mice could be rescued by dampening the DNA damage  
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Figure 2.4 Brca1SF hypomorphic allele shows synthetic lethality with Atm 
nullizygosity. 
A. Atm heterozygosity rescues the sub-Mendelian ratio of Brca1SF/SF mice. However, 
no live Atm-/-Brca1SF/SF double mutant mice are recovered at weaning.  
B. Heterozygous and homozygous deletion of Chk2 partially rescue the sub-Mendelian 
ratio of Brca1SF/SF mice. This cohort is the F2 generation of intercross with Chk2 mice 
that are originally on B6 background, which likely causes the more unfavorable ratio 
of Brca1SF/SF mutant compared to the cross with Atm mice (mixed background). 
C. One Atm-/-Brca1SF/SF embryo is found at E9.5. The embryo appears slightly smaller 
than either Atm-/- or Brca1SF/SF single mutant. Scale bar: 1 mm. 
D. One Atm-/-Brca1SF/SF embryo is found at E13.5 that is much smaller than other 
siblings. The MEFs from this embryo fail to plate in culture while MEFs from all 
other embryos survive. Scale bar: 1 cm.  
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response or whether the role for ATM in HDR becomes important in this context, 
mating was performed to generate Atm-/-Brca1SF/SF and Chk2-/-Brca1SF/SF mice. 
Heterozygous Atm deletion, as well as heterozygous and homozygous deletion of 
Chk2, partially rescued the Brca1SF/SF mice (Figure 2.4 A and B), indicating that a 
DNA damage response reduces the survival of Brca1SF/SF mice. However, we did not 
recover viable Atm-/-Brca1SF/SF double mutants, indicating that ATM is required for the 
survival of Brca1SF/SF mice (Figure 2.4A; see Appendix Figure A.1A for the 
photograph). These results suggest that the lethality associated with complete loss of 
ATM is due to another function of ATM such as in DNA repair, specifically HDR. 
 To approximate at what stage Atm-/-Brca1SF/SF mice die, timed mating was set 
up to harvest embryos. Atm-/-Brca1SF/SF embryos were underrepresented at mid-
embryogenesis, although at both embryonic day E9.5 (Figure 2.4C) and E13.5 (Figure 
2.4D) one double mutant was recovered; both embryos appeared smaller than their 
single mutant littermates. Mouse embryonic fibroblasts (MEFs) derived from the 
E13.5 embryo failed to proliferate in culture. Overall, our results indicate that Atm 
nullizygous mutation leads to a synthetic, embryonic lethality in the context of the 
Brca1SF missense mutation, in contrast to the rescue of viability observed with the 
Brca1Δ11 allele. The difference between the two Brca1 alleles may relate to the BRCT 
domain, which is intact in the protein expressed from the Brca1Δ11 allele (38). 
HDR in Brca1SF primary mouse fibroblasts is further reduced by ATM 
inhibition.  
To investigate the mechanism of synthetic lethality, we examined HDR in primary 
cells derived from mice carrying an integrated DR-GFP reporter, a CMV-rtTA 
transactivator, and a doxycycline (Dox)-inducible transgene of I-SceI endonuclease 
(TRE-I-SceI) that allow for highly efficient DSB formation (27, 39). Primary ear 
fibroblasts from the Brca1SF/SF and Atm-/- mice showed 3- and 2-fold reductions in 
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HDR, respectively (Figure 2.5 A and B, left panels). To take into account animal 
variation in I-SceI expression, the percent GFP+ cells was normalized to total DSB 
repair events using a site-loss assay (Figure 2.5C), which provided an estimate on the 
fraction of HDR among total repair events, i.e., % HDR (in graphs showing DR-GFP 
assays in Chapter 2 and 3, green and gray bars represent % GFP+ and % HDR, 
respectively). The site-loss assay helped confirm the fold of reduction in HDR in these 
mutants (Figure 2.5 A and B, right panels). The HDR defect observed in Atm mutant 
fibroblasts was interesting, given that the influence of ATM loss on HDR varies 
between reports. The percentage of site loss for WT and Atm-/- ear fibroblasts was 
similar (44% for each), indicating that total repair efficiency was similar for both 
genotypes (Figure 2.5B, right panel). Thus, the fraction of HDR among total repair 
events was 25% for WT and 12% for Atm-/- ear fibroblasts, confirming that loss of 
ATM reduces HDR by 2-fold in this assay, whereas the rest of the repair events in 
Atm-/- cells were likely compensated by NHEJ. Unlike the delay of HDR seen in Atm-/- 
ES cells, a similar reduction in HDR in Atm-/- compared with control ear fibroblasts 
was observed at all time points following DSB induction (from 24 to 96 hr; other 
primary cell experiments were typically analyzed at 48 hr), suggesting persistent HDR 
defect (Figure 2.5D). Other somatic cell types from Atm-/- mice, e.g., splenic B cells 
(Figure 2.5E) and mammary epithelial cells (Figure 2.5F), showed similarly impaired 
HDR, as did a distinct Atm mutant (30) (Figure 2.5G; ear fibroblasts and mammary 
cells in upper and lower panels, respectively). Thus, loss of ATM causes a defect in 
HDR in mouse primary adult somatic cells, as measured by the DR-GFP reporter 
assay, although not to the same extent as with the hypomorphic Brca1SF allele (Figure 
2.5 A and H). Although heterozygous mutations of BRCA1 or ATM are associated to 
breast cancer risks in carries, heterozygosity of Brca1SF or Atm in mice did not  
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Figure 2.5 Primary somatic cells from Brca1SF and Atm mutant mice show defects 
in HDR. 
A. Examining HDR in primary cells using the inducible I-SceI/DR-GFP system. 
Primary ear fibroblasts from Brca1SF/SF mice have a ~3-fold reduction in HDR 
compared to WT cells either by analyzing % GFP+ alone or by normalizing % GFP+ to 
% I-SceI site loss (i.e., % HDR, the fraction of HDR in overall repair; see Figure 2.5C 
below). I-SceIS/S: these mice are homozygous for the TRE-I-SceI allele when indicated. 
(n≥9) 
B. Primary ear fibroblasts from Atm-/- mice have a 2-fold reduction in HDR. (n≥10) 
C. To determine DSB efficiency in the DR-GFP reporter, the sequence flanking the 
DSB site in the SceGFP is amplified by primers, followed by in vitro digestion with I-
SceI endonuclease. Repair by either HDR or imprecise NHEJ results in loss of the I-
SceI site, which leaves an intact 0.9-kb product (right gel) in comparison to the 
digested 0.7- and 0.2-kb bands. This primer set does not amplify SSA or unrepaired 
events. The % site loss is calculated by dividing the intensity of 0.9-kb band with the 
sum of 0.9-kb plus 0.7-kb (* accounted for size difference) band. The % HDR, which 
normalizes % GFP+ with % site loss, represents the ratio of HDR among total repair 
events. Dox: doxycycline. 
D. Time course of Dox treatment shows that Atm-/- fibroblasts consistently have lower 
HDR than control cells (Atm+/- or WT). Cells are exposed to Dox continuously for 24, 
48, or 72 hours or for a 48-hour pulse followed by 48-hour recovery to allow time for 
repair. (n≥3 for all time points except n=1 for 72h) 
E. Primary splenic B cells from Atm-/- mice have a 2-fold reduction in HDR compared 
to WT cells (left). The % GFP+ is measured from the purified B220+ B cells stimulated 
with LPS and IL4 together with Dox for 5 days. The low dose of Dox (0.25 µg/ml) 
used here does not affect class switching per se, which is 3-fold lower in Atm-/- than 
WT B cells (right). (n=3) 
F. Primary mammary epithelial cells harvested from Atm-/- mice have a ~2-fold 
reduction in HDR. Mammary gland from a 12-week-old Atm-/- mouse shows relatively 
normal elongation of ductal trees that fill the fat pad, albeit with less secondary 
branching compared to the littermate control (right panel). (n≥4) 
G. All the Atm experiments in the paper are performed with the Atmb mutant allele 
with the exons encoding the kinase domain deleted (29). For comparison, another 
strain of Atm mutant mice (Atmw allele) is examined, which contains an exon deletion 
upstream of the kinase domain (30). Both Atm mutant alleles do not produce 
detectable ATM protein in fibroblasts (27). Primary ear fibroblasts and mammary cells 
harvested from the Atmw mutant mice show a similar 2-fold reduction in HDR as the 
Atmb allele. (n≥3) 
H. Primary mammary epithelial cells from Brca1SF/SF mutant mice have a ~3-fold 
reduction in % HDR. (n≥3) 
  
	 39 
Figure 2.5 
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Figure 2.5 (Continued) 
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significantly affect HDR in either fibroblasts or mammary cells (Figure 2.5 A and B, 
see % HDR for normalized results). 
 Although ATM deficiency by itself caused only a 2-fold HDR defect (Figure 
2.5B) and ATMi-treated WT cells showed a mild 1.6-fold HDR reduction (Figure 
2.6A), ATM inhibition in Brca1SF/SF ear fibroblasts greatly exacerbated their HDR 
defect, such that the overall reduction of HDR relative to DMSO-treated WT cells was 
14-fold (Figure 2.6A, % GFP+ 0.8 vs. 11.2). The large HDR reduction in ATMi-
treated Brca1SF/SF cells was not related to changes in cell cycle distribution (Figure 
2.6B). At the dose of 3 µM used, ATMi generally caused a 1.2-fold reduction in HDR 
in Atm-/- primary fibroblasts but this was still significantly less than the 1.6-fold 
reduction in WT cells (Figure 2.6A), which could be attributed to the off-target effects 
of the ATMi. Treatment with a CHK2 inhibitor slightly reduced HDR in the 
Brca1SF/SF ear fibroblasts, but the extent was not significantly different from that in 
WT or Atm-/- cells (Figure 2.6C), consistent with the notion that the reliance on ATM 
in the Brca1SF mutant is related to its role in DNA repair. 
 We performed a similar analysis in MEFs. In untreated Brca1SF/SF MEFs, the 
reduction in HDR was larger than in ear fibroblasts, but was similar to ES cells (~8-
fold; Figure 2.6D), suggesting that BRCA1 has a more pronounced role in HDR in 
embryonic cells than adult cells. Conversely, HDR was reduced to a somewhat lesser 
extent in Atm-/- MEFs (Figure 2.6D) and ATMi-treated WT MEFs (Figure 2.6E), 
indicating a less critical role for ATM in embryonic cells (see Appendix Figure A.1B 
for olaparib sensitivity in MEFs). This differential dependence of BRCA1 and ATM 
in adult cells versus embryonic cells is also confirmed by normalizing HDR with the 
site-loss assay. However, as with the ear fibroblasts, the HDR defect in Brca1SF/SF 
MEFs was further exacerbated by ATMi treatment, such that the overall reduction in  
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Figure 2.6 ATM inhibition exacerbates HDR defect in Brca1SF/SF primary cells. 
A. ATMi treatment (3 µM) reduces HDR in Brca1SF/SF ear fibroblasts to a greater 
extent than in WT cells. (n≥3) 
B. Cell cycle profiles show no significant difference between WT and Brca1SF/SF 
primary ear fibroblasts following ATMi treatment. Note that these cells are from 
+Dox 48 hr treatment and thus have higher G1 ratio than the profiles in Figure 2.10C. 
(n=2) 
C. Inhibition of CHK2 slightly reduces HDR in Brca1SF/SF ear fibroblasts, but the 
extent is not significantly different from that of WT or Atm-/- cells. * Brca1SF/SF: 
Atm+/+ or Atm+/- (n=3 for WT and Brca1SF/SF, n=2 for Atm-/-) 
D. Brca1SF/SF primary MEFs show a substantial reduction in HDR (~8-fold for % 
GFP+; 6-fold for % HDR) compared to WT MEFs, whereas the reduction in Atm-/- 
MEFs is less profound (~1.5-fold). (n≥3 except n=2 for Brca1SF/SF) 
E. ATMi treatment (3 µM) reduces HDR in Brca1SF/SF MEFs to a greater extent than 
in WT MEFs. Similar to ATM loss, ATMi also shows less effect in suppressing HDR 
in WT MEFs compared to WT ear fibroblasts. (n≥3 except n=2 for Atm-/-) 
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Figure 2.7 ATM inhibition exacerbates SSA defect in Brca1SF/SF primary cells. 
A. Treatment with Dox induces I-SceI endonuclease, which introduces a DSB in the 
DR-GFP reporter that if repaired by HDR restores GFP expression. The DSB can also 
be repaired via SSA if resection exposes complementary strands in both SceGFP and 
iGFP which then anneal to give rise to a shortened reporter product. SSA events are 
detected using a specific primer set (blue forward/reverse) and the intensity is 
normalized to the structurally intact reporter using primers flanking SceGFP (blue 
forward, black reverse), followed by comparison between control and mutants. A 
positive control of this assay is depicted in the box showing that Brca2Δ27/Δ27 primary 
fibroblasts have severely reduced HDR but increased SSA (40). 
B. The relative levels of SSA are reduced by ~2.5 fold in Atm-/- ear fibroblasts 
compared to control cells (WT or Atm+/-). The SSA product is observed only when I-
SceI is induced by Dox. Relative fold is calculated between control and mutant cells 
on the same gel. (n=7) 
C. The relative levels of SSA in Brca1SF/SF ear fibroblasts are ~3-fold lower than in 
control cells, and ATMi treatment further reduces SSA in Brca1SF/SF cells. 
*Brca1SF/SF: Atm+/+ or Atm+/- (n=8)  
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HDR was 20-fold compared to WT cells (Figure 2.6E, % GFP+ 0.4 vs. 7.9). Overall, 
these results demonstrate that ATM is critical for much of the residual HDR in the 
Brca1SF/SF cells, potentially accounting for the synthetic lethality observed in double 
mutant mice. 
ATM kinase inhibition further reduces SSA in Brca1SF mutant cells.  
Evidence suggests that both BRCA1 and ATM promote DNA end resection (6, 20, 
40). End resection is a common step for HDR and another homology-based DSB 
repair pathway, single-strand annealing (SSA), in which complementary single strands 
generated by resection at sequence repeats anneal, resulting in a deletion of the 
sequence between the repeats; thus, a defect in end resection compromises both 
pathways (40). By contrast, defects in downstream steps of HDR such as RAD51 
filament formation increase SSA. Using a PCR-based assay with the DR-GFP reporter 
to quantify SSA (41) (Figure 2.7A), we found that loss or inhibition of ATM reduced 
SSA by 2 to 2.5 fold in ear fibroblasts (Figure 2.7 B and C), as reported previously for 
mouse ES cells (42). The decreased levels of SSA are comparable to our HDR results 
and are consistent with a role for ATM in the end resection step of DSB repair.  
 As with HDR, Brca1SF/SF cells showed a 3-fold reduction in SSA (Figure 
2.7C), similar to cells carrying the cognate human BRCA1 mutation (43). Notably, 
ATM inhibition further decreased SSA in Brca1SF/SF cells for an overall 10-fold 
reduction compared to DMSO-treated control cells, indicating that both end resection-
dependent DSB repair pathways, HDR and SSA, rely heavily on ATM in Brca1SF 
mutant cells.  
53bp1 deletion does not restore HDR in ATM-deficient cells.  
The NHEJ protein 53BP1 suppresses DNA end resection, such that loss of 53BP1 
significantly restores HDR in BRCA1-deficient cells (5, 6). Thus, we hypothesized 
that loss of 53BP1 would rescue the survival of Atm-Brca1SF double mutant animals. 
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As predicted, viable Atm-/-Brca1SF/SF53bp1-/- mice were recovered (Figure 2.8A; see 
Appendix Figure A.1C for survival analysis of the Atm-Brca1SF-53bp1 mutant mice). 
Interestingly, 53bp1 heterozygosity also led to a rescue of Atm-/-Brca1SF/SF animals, 
although partial. In Brca1SF/SF ear fibroblasts (Figure 2.8B) and mammary epithelial 
cells (Figure 2.8C), homozygous deletion of 53bp1 fully rescued the HDR defect 
(Figure 2.8 B and C), indicating that the functions of BRCT domain are involved in 
counteracting 53BP1 (44-46). Interestingly, in both cell types, heterozygosity for the 
53bp1 mutation also led to a moderate increase in HDR (~50%) (Figure 2.8 B and D). 
This may be in part related to the reduced levels of 53BP1 protein in the 53bp1 
heterozygous cells (Figure 2.8E). Thus, even partial loss of 53BP1 protein increases 
HDR in the Brca1SF mutant setting. 
 We investigated whether 53bp1 mutation would also rescue HDR defects in 
Atm mutant cells as it does in Brca1 mutant cells. Importantly, Atm-/-53bp1-/- ear 
fibroblasts showed the same ~2-fold decrease in HDR as Atm-/- cells (Figure 2.9A). 
The lack of rescue of the HDR defect in Atm mutant cells by 53bp1 loss indicates that 
ATM operates separately from the BRCA1-53BP1 antagonism in HDR. Consistent 
with this interpretation, HDR was ~2-fold lower in Atm-/-Brca1SF/SF53bp1-/- ear 
fibroblasts compared with Brca1SF/SF53bp1-/- cells (Figure 2.9B), which is analogous 
to the HDR response following ATM loss in WT cells (Figure 2.9A). This indicates 
that 53bp1 loss specifically rescues the HDR defect caused by the Brca1SF mutation 
but not that of the Atm mutation. 
 We also analyzed HDR in Brca1SF/SF53bp1-/- ear fibroblasts treated with the 
ATMi. HDR was significantly restored in Brca1SF/SF53bp1-/- cells compared to 
Brca1SF/SF cells, but treatment with ATMi still reduced it by ~30%, similar to the fold 
reduction in WT cells (Figure 2.9C). HDR in 53bp1-/- cells was also reduced by ATMi  
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Figure 2.8 HDR defect in Brca1SF/SF primary cells is rescued by loss of 53BP1. 
A. Heterozygous and homozygous deletion of 53bp1 rescue the viability of Atm-/-
Brca1SF/SF double mutant mice. 
B. Homozygous deletion of 53bp1 fully restores the levels of HDR in Brca1SF/SF ear 
fibroblasts. Heterozygous deletion of 53bp1 in Brca1SF/SF fibroblasts also increases 
HDR by ~1.5-fold. *53bp1-/-: Brca1+/+ or Brca1SF/+ (n≥3 except n=2 for 53bp1-/-) 
C. Homozygous deletion of 53bp1 restores HDR in Brca1SF/SF mammary cells. (n≥3) 
D. Heterozygous deletion of 53bp1 significantly increases HDR in Brca1SF/SF 
mammary epithelial cells by ~1.6-fold. (n≥3) 
E. The level of 53BP1 protein is partially reduced in 53bp1+/- compared to 53bp1+/+ 
primary ear fibroblasts.  
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Figure 2.9 ATM promotes HDR independently of the BRCA1-53BP1 antagonism. 
A. 53BP1 loss does not restore the 2-fold HDR defect in Atm-/- ear fibroblasts. (n≥4) 
B. Loss of Atm in Brca1SF/SF53bp1-/- ear fibroblasts still reduces HDR by ~2-fold. (n=5 
for double mutant, n=2 for triple mutant) 
C. Unlike in Brca1SF/SF ear fibroblasts, ATMi treatment (3 µM) reduces HDR in 
Brca1SF/SF53bp1-/- cells to a similar extent as in WT or 53bp1-/- cells. (n≥3 except n=2 
for 53bp1-/-) 
D. ATMi treatment reduces HDR in 53bp1-/- ear fibroblasts to a similar extent as in 
WT cells. (n≥5) 
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to a similar extent as in WT cells (Figure 2.9D). Thus, 53BP1 loss does not rescue the 
HDR defect caused by either ATM loss or inhibition. 
 Although sensitive to ATM inhibition, the level of HDR in the 
Brca1SF/SF53bp1+/- cells was still higher than in the Brca1SF/SF cells upon ATMi 
treatment (Figure 2.9C, with ATMi, % GFP+ 1.8 vs. 0.9), indicating that 53bp1 
heterozygosity is effective in partially restoring HDR in the presence of ATMi. Thus, 
it seems plausible that HDR in Atm-/-Brca1SF/SF53bp1+/- mice may be restored above a 
threshold level that permits their survival (Figure 2.8A). 
ATM supports HDR and SSA independently of the BRCA1-53BP1 antagonism. 
To further examine the interaction of the Atm, Brca1SF, and 53bp1 mutations in HDR, 
we examined DNA damage-induced RAD51 and RPA foci in primary ear fibroblasts 
(Figure 2.10 A and B). As seen previously in other cell types, both Atm-/- and 
Brca1SF/SF fibroblasts showed a significant decrease compared to WT in the 
percentage of cells positive for RAD51 and RPA foci following ionizing radiation (IR) 
(~25% and ~40% reduction, respectively) (17, 18, 20, 31), whereas 53bp1-/- cells 
showed a small increase (~10%). In Brca1SF/SF53bp1-/- cells, RAD51 and RPA focus 
formation was significantly rescued compared to Brca1SF/SF cells, approaching that of 
WT cells (Figure 2.10 A and B; compare column a, c, and f). No significant changes 
in cell cycle distribution were observed in any of the genotypes at the time point of 
immunofluorescence staining (2 hours after IR; Figure 2.10C). 
 Consistent with the lack of rescue of HDR by 53BP1 loss (Figure 2.9A), the 
number of RAD51 and RPA foci-positive Atm-/-53bp1-/- cells remained lower than WT 
cells (Figure 2.10 A and B; column a and e). Interestingly, however, a small increase 
was noted for the Atm-/-53bp1-/- compared to Atm-/- cells, although this did not reach 
statistical significance (Figure 2.10 A and B; column b and e). It is possible that more 
recombination complexes are able to form with loss of 53BP1 that are not proficient at  
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Figure 2.10 Nuclear foci analysis confirms the epistasis of Atm-Brca1SF-53bp1 in 
resection and HDR. 
A & B. Loss of Atm in Brca1SF/SF53bp1-/- primary ear fibroblasts still reduces % 
RAD51+ (A) and % RPA+ (B) cells following IR (column f versus h), supporting an 
independent role of ATM in resection and HDR. Although 53bp1+/- rescues the Atm-/-
Brca1SF/SF animal viability, fibroblasts derived from the animal have the lowest levels 
of RAD51 and RPA foci formation among all the mutants (column g, note the limited 
difference between IR+ and IR−), suggesting a severe repair defect in the Atm-Brca1SF 
double mutant. Primary ear fibroblasts are plated overnight, treated with or without 10 
Gy IR, and allowed for recovery for 2 hr before immunostaining. The analysis is 
performed with at least three animals for IR+ samples, each with ~200 total cells 
counted. For IR− samples, at least two animals are analyzed, except just one for RPA 
foci in triple mutant. 
C. Cell cycle profiles show no apparent difference between WT and mutant fibroblasts 
2 hr after 10 Gy IR (i.e., the same condition for staining of DNA damage foci). 
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Figure 2.10 
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Figure 2.10 (Continued) 
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late-stage HDR (47); alternatively, more foci may become visible due to increased 
resection lengths (see Appendix Figure A.1E for quantification of the RPA foci 
number). The Atm-/-Brca1SF/SF53bp1-/- triple mutant also demonstrated reduced 
RAD51 and RPA foci-positive cells compared to Brca1SF/SF53bp1-/- (Figure 2.10 A 
and B; column f and h), further supporting a role for ATM in generating end-resected 
intermediates for RAD51 filament formation in cells with compromised BRCA1 and 
53BP1 functions. 
 These results suggest that ATM functions in HDR independently of 53BP1 and 
BRCA1 and that SSA in ATM-deficient cells would also not be fully restored by 
53BP1 loss. While 53bp1-/- cells had an ~1.5-fold increase in SSA, Atm-/-53bp1-/- cells 
showed the same ~2-fold reduction as Atm-/- cells (Figure 2.11A). Similarly, while 
SSA was restored in Brca1SF/SF53bp1-/- cells, it was reduced by ~2-fold in triple 
mutant Atm-/-Brca1SF/SF53bp1-/- cells (Figure 2.11A) and in ATMi-treated double 
mutant cells (Figure 2.11B). These results are consistent with a role for ATM in 
promoting resection-dependent repair independently of the BRCA1-53BP1 
antagonism. 
 
Discussion 
The epistatic relationship of BRCA1 and ATM in HDR is not well understood in 
mice, in part because Brca1 nullizygosity leads to early embryonic lethality (28). 
However, the viability of the hypomorphic Brca1SF allele with a missense mutation in 
the BRCT domain (31) has allowed us to uncover synthetic lethality upon Atm loss. 
The findings support a critical role for ATM in maintaining a threshold level of HDR 
necessary for viability in the context of a breast cancer-associated Brca1 mutation.  
Inhibition of ATM activity in Brca1SF/SF cells reduces HDR by up to 20-fold relative to 
WT cells. As HDR proficiency is essential for proliferation during mouse  
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Figure 2.11 ATM promotes SSA independently of the BRCA1-53BP1 
antagonism. 
A. The levels of SSA in both Atm-/-53bp1-/- and Atm-/-Brca1SF/SF53bp1-/- ear fibroblasts 
show the similar 2-fold reductions as in Atm-/- cells. (n=4 for Atm-/-53bp1-/-, n=2 for 
triple mutant).  
B. While loss of 53bp1 rescues the SSA defect in Brca1SF/SF ear fibroblasts, treatment 
with ATMi still reduces SSA in the Brca1SF/SF53bp1-/- cells by ~2-fold as in WT cells. 
(n≥3) 
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development (1), the contribution of ATM to HDR in Brca1SF/SF mice provides a 
mechanism for the compromised viability of Atm-Brca1SF double mutant mice. 
Previous studies have also demonstrated synthetic lethality of Atm mutant mice 
with deficiency of other DNA damage response factors such as H2ax and Parp1 (48, 
49). However, the mechanisms of synthetic lethality appear to differ from what we 
report here. In particular, Atm-H2ax double mutant cells do not show significant 
exacerbation in HDR defects compared to single mutant cells (26). Further, synthetic 
lethality of the Atm-Parp1 mouse is likely due to deficiency in distinct pathways, 
given that PARP1 loss impairs single-strand break repair. The defect in HDR we 
report for Atm mutant mouse cells, however, makes it reasonable to consider that Atm-
Parp1 mice are unviable due to a role for ATM in repair of lesions generated by 
PARP1 loss (50).  
Different BRCA1 mutations affect the genetic interaction with ATM  
In addition to the Brca1SF BRCT mutation, we have also examined the genetic 
interaction of ATM with another Brca1 allele, Brca1tr truncational mutation (51), 
which mimics a breast cancer founder mutation 2800delAA (52). The Brca1tr allele is 
predicted to express a BRCA1 protein truncated in the exon 11-encoding region, 
leading to deletion of the C terminus including the BRCT domain (Appendix Figure 
A.2A). The Brca1tr/tr mice were born at sub-Mendelian ratio (observed 3, expected 11; 
Appendix Figure A.2B). Whereas the sub-viability of Brca1tr/tr mice was rescued by 
Atm heterozygosity (observed 18, expected 22), it was further reduced by nullizygosity 
of Atm (observed 1, expected 11). These results share similarity with the synthetic 
lethality of the Atm-Brca1SF mutant mice (Figure 2.4A). HDR in Brca1tr/tr fibroblasts 
was suppressed by ATM deficiency to a greater extent than in WT cells, although not 
as much as that in Brca1SF/SF cells (Appendix Figure A.2 D and E), suggesting a 
moderate dependence on ATM for HDR in the Brca1tr mutant. By contrast, in a 
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different Brca1 hypomorphic mutant, BRCA1 exon 11-skipping isoform that lacks the 
central region but retains the BRCT domain (53), ATM deficiency leads to distinct 
HDR response that we will describe in Chapter 3. These observations raise the 
possibility that ATM has special roles in promoting HDR in the context of different 
BRCA1 mutations. Further work is needed to elucidate the mechanisms as well as the 
significance in the human context.  
Context-dependent roles of ATM in HDR 
While some studies have observed a role for ATM in HDR (17, 18), other studies have 
not (24-27). We previously did not detect a significant defect in HDR in Atm-/- primary 
mouse fibroblasts using an electroporation method with an I-SceI expression vector 
(27), which in primary cells is variable and relatively inefficient (~20%), such that the 
fraction of DSB repair events involving HDR could not be determined (see Appendix 
Figure A.3 for I-SceI transfection experiments in primary cells). The Dox-inducible I-
SceI system utilized in this study, by contrast, results in DSB formation in a 
substantially higher percentage of cells (~50%) (39). This allows us to normalize HDR 
levels to total repair events to determine the percentage of cells that had repaired the 
DSB by either HDR or imprecise NHEJ. We present evidence here that primary 
somatic cells of multiple tissue types from Atm mutant mice consistently have a ~2-
fold reduction in HDR following an I-SceI-induced DSB. In contrast to somatic cells, 
our results show that ATM loss in ES cells causes only a transient delay in HDR. The 
lack of a defect at later time points in ES cells in DR-GFP experiments is consistent 
with findings from other groups (25, 26).  
Several possibilities may account for the different HDR response in Atm-/- ES 
cells. First, embryonic cells likely have a greater reliance on BRCA1 than ATM for 
HDR compared to somatic cells. We observed that Brca1SF mutation causes a greater 
HDR defect in MEFs than adult ear fibroblasts, whereas Atm mutation shows the 
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opposite trend (Figures 2.5 and 2.6). Consistent with this notion, Brca1-null mice are 
lethal (54), unlike the viability of Atm-null mice at birth (29, 30). Second, mouse ES 
cells have unique properties in DNA repair and cell cycle profiles compared to more 
differentiated cell types (55, 56). Studies suggest that mouse ES cells preferably use 
HDR over NHEJ for DSB repair (57). The high enrichment in S/G2 phases in these 
cells may facilitate phosphorylation of BRCA1 for its functions or provide high CDK 
activity for resection regulation (58-60), thus attenuating the requirement for ATM. 
The short G1 phase and lack of the G1/S checkpoint may also render mouse ES cells 
more dependent on replication-coupled repair and thus more reliance on the ATR 
kinase (55). Interestingly, studies in Xenopus extracts show that ATR can be activated 
directly by the MRN complex and can also facilitate CtIP-mediated resection of clean 
DSBs independently of ATM in the presence of the EXO1 exonuclease (61, 62). It is 
possible that ATR and/or EXO1 can serve as alternative pathways for resection in 
Atm-/- ES cells in the context of I-SceI-induced DSBs (see Appendix Figures A.4-6 for 
additional analysis of ES cells). Third, Atm-/- ES cells may still have defects in 
repairing high levels of DSBs or specific breaks located in heterochromatic regions 
compared to a single break at the DR-GFP reporter at Pim1 locus. Despite the lack of 
significant defect in DR-GFP experiments, Atm-/- mouse ES cells are clearly very 
sensitive to olaparib (26, 63), similar to the phenotypes in Atm mutant human cells 
(64, 65). This suggests that loss of ATM protein indeed causes certain HDR deficiency 
that renders the cells unable to cope with global DSB accumulation following PARP 
inhibition. This may be due to the excessive DSB formation that highly activates the 
ATM pathway or the structural lesions generated by trapping of PARP1/2 proteins that 
involve ATM activity in the repair of blocked ends (33, 50, 66). Furthermore, PARPi-
induced DSBs could be located in heterochromatins throughout the genome that 
depend on ATM for efficient repair (67). 
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ATM operates in HDR independently of the BRCA1-53BP1 antagonism 
Although the reduced HDR in Atm-/- cells could be associated with a role for ATM in 
later steps of recombination (47, 68), the shared defects in both HDR and SSA 
together with the reduced RPA focus formation we and others observe (19, 20) argue 
that ATM loss impacts early steps of recombination, such as modulating the extent of 
end resection (21-23, 69-71) or the removal of Ku from DNA ends (72). HDR defects 
in Atm mutant cells have also been related to indirect aspects of ATM activity in 
chromatin relaxation (22, 73). A role for ATM in promoting end resection in HDR 
during S/G2 may seem contradictory, considering that ATM also functions in NHEJ: 
In G1 cells, ATM inhibits end resection by promoting 53BP1 functions (3, 7) and the 
γH2AX/MDC1 assembly (74). However, removing either 53BP1 or H2AX allows 
ATM-dependent resection to be observed (74-77), though G1 phase resection is not 
expected to be productive for HDR due to other restrictive mechanisms (16). 
Importantly, although not usually essential in wild-type cells, our results indicate that 
ATM becomes crucial for supporting the residual end resection and HDR in Brca1SF 
hypomorphic cells, which is likely critical for the survival of Brca1SF mice. 
 Our genetic epistasis indicates that the HDR and SSA defects in Atm-/- primary 
cells cannot be rescued by 53bp1 deletion, distinguishing the function of ATM from 
the 53BP1-mediated suppression of BRCA1 and HDR. Further, while 53bp1 loss can 
restore HDR and SSA in Brca1SF/SF cells, as with other Brca1 mutant alleles, ATM 
deficiency in Brca1SF/SF53bp1-/- cells reduces both types of DSB repair to a similar 
extent as in WT or 53bp1-/- cells. Therefore, these observations suggest that ATM has 
a direct function in promoting end resection independently of the BRCA1-53BP1 
mutual antagonism (Figure 2.12). We do not rule out the possibility that the BRCA1SF 
protein, which maintains ATM-phosphorylation sites (78), requires ATM  
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Figure 2.12 Model: The interplay of ATM and BRCA1 in HDR. 
In Brca1+/+ cells, ATM has a minor role in HDR that operates independently of the 
BRCA1-53BP1 antagonism. Loss of ATM in this setting only reduces HDR to a 
moderate degree (2-fold in mouse somatic cells) and does not compromise overall 
viability, e.g., in mouse development. However, in the context of a breast cancer-
derived S1598F mutation on mouse BRCA1 that disrupts its BRCT domain functions, 
ATM becomes essential for supporting the residual end resection and HDR in 
Brca1SF/SF cells as well as the viability of Brca1SF/SF mice.  
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phosphorylation to sustain its hypomorphic function in HDR, in which case ATM may 
not be an entirely independent player but have crosstalk with BRCA1.  
A number of mutations in the BRCT domain of BRCA1 have been associated 
with breast cancer (https://research.nhgri.nih.gov/projects/bic/), including S1655F 
equivalent to the mouse S1598F mutation. It remains to be seen how tumors carrying 
these mutations respond to DNA damaging agents upon ATM loss-of-function. The 
downregulation of resection suppressors such as 53BP1 has been identified as a 
mechanism for the acquired resistance to PARP inhibition in BRCA1-deficient 
mammary tumors (79-82). Given that ATM still plays a role in HDR in these resistant 
cells, we envision that inhibition of ATM kinase activity may have therapeutic 
potential for certain types of BRCA1-deficient cancers with acquired resistance to 
PARP inhibitor therapy. 
 
Contribution 
Elizabeth Kass (Maria Jasin lab) performed the Brca1SF and Brca1SF-53bp1 mammary 
experiments and provided materials for the I-SceIS/S experiments. Wei-Feng Yen 
(Jayanta Chaudhuri lab) performed the Atm B cell experiments. Chun-Chin Chen 
performed all the rest of the experiments. 
 
Materials and Methods 
Mouse care and genotyping. The care and use of mice were performed with the 
approval of the Memorial Sloan Kettering Cancer Center (MSKCC) Institutional 
Animal Care and Use Committee in accordance with institutional guidelines. Genomic 
DNA was extracted from tail tips using Gentra Puregene Mouse Tail Kit (Qiagen). 
PCR reactions were performed with PuReTaq PCRbeads (GE Healthcare) with ~100 
ng purified genomic DNA. 
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Pim1Drgfp mice (27) were genotyped using primers Pim1Ex1F 5’-AAG ATC 
AAC TCC CTG GCC CAC CTG CG-3’; Pim1Ex4R 5’-TGT TCT CGT CCT TGA 
TGT CG-3’; Hyg3A 5’-CCG CTC GTC TGG CTA AGA T-3’ under the following 
conditions: 94°C/3 min; 35 cycles of 94°C/30 sec, 62.9°C/45 sec and 72°C/1 min; and 
a final extension of 72°C/5 min. PCR products (WT: 786 bp; Targeted: 958 bp) were 
separated on a 1% agarose gel. 
TRE-I-SceI mice (39) (founder line #10) were genotyped using primers 
F10.For.Chr6 5′-CTA CAT GTG GCA ACT GGC TCA ATC A-3′; F10.Rev.350 5′-
CTG AGC CAT CTC TCT AGC CCA-3′ and SCE.Rev 5′-CTG CTT ATA TAG GCC 
TCC CAC CGT ACA-3′ under the following conditions: 95 °C/3 min; 32 cycles of 
95 °C/30 sec, 58.5 °C/30 sec, and 72 °C/1 min; and a final extension of 72 °C/5 min. 
PCR products (WT: 350 bp; I-SceI allele: 550 bp) were separated on a 1.5% agarose 
gel. The CMV-rtTA transgene was genotyped using rtTA-specific forward primer 5′-
GCT TGG TGT AGA GCA GCC TAC AC-3′ and reverse primer 5′-CAG CGC TGA 
GTG CAT ATA ACG CG-3′ under the following conditions: 94 °C/4 min; 35 cycles 
of 94 °C/30 sec, 55 °C/30 sec, and 72 °C, 30 sec, and a final extension of 72 °C/5 min. 
For CMV-rtTA PCR, the reaction contains 150-200 ng of genomic DNA and 2% 
DMSO. An ∼310 bp product indicates presence of the transgene.  
Atmb mice (29) were genotyped using primers AtmWTFwd 5’-TGT AAT GTG 
CCT TAA AGA ACC TGG-3’; AtmNullFwd 5’-GGA AAA GCG CCT CCC CTA 
CCC-3’; AtmRev 5’-CCT CCT CAT ATT TGT AAC ACG CTG-3’ under the 
following conditions: 94°C/2 min; 35 cycles of 94°C/30 sec, 62°C/45 sec, and 
72°C/45 sec; and a final extension of 72°C/5 min. PCR products (WT: 362 bp; 
Mutant: ~500 bp) were resolved on a 1.5% agarose gel; note that a faint band may 
appear between the two PCR products. 
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Atmw mice (30) were genotyped using primers AtmF 5’-GAC TTC TGT CAG 
ATG TTG CTG CC-3’; AtmB 5’-CGA ATT TGC AGG AGT TGC TGA G-3’; AtmN 
5’-GGG TGG GAT TAG ATA AAT GCC TG-3’ under the following conditions: 
94°/2 min; 35 cycles of 94°C/20 sec, 58°C/30 sec, and 72°C/30 sec; and a final 
extension of 72°C/5 min. WT (162 bp) and mutant (440 bp) PCR products were 
separated on a 1.5% agarose gel. 
Brca1S1598F mice (31) were genotyped using primers S1598F.for 5’-CCC TTG 
TGC ACC TCC AGA GA-3’; S1598F.rev 5’-GCC ACG CCT ATG AAG GCT CT-3’ 
and LNL3xpA 5’-GAC CTG CAG CCC AAG CTA GC-3’ under the following 
conditions: 94°C/3 min; 35 cycles of 94°C/30 sec, 58°C/30 sec and 72°C/30 sec; and a 
final extension of 72°C/5 min. PCR products (WT: 259 bp; Mutant: 117 bp) were 
separated on a 1.5% agarose gel.  
53bp1 mice (83) were genotyped using primers exon4 sense 5’-GAT TTT 
GCC TTA CCC AGT TCC CGA-3’; neo sense 5’-CTA CCC GGT AGA ATT GAC 
CTG CA-3’ and intron antisense 5’-CCT TCT ATT CTA CTT CAG GCT CTG G-3’ 
following the same condition as the Brca1S1598F mice genotyping PCR. PCR products 
(WT: ~300 bp; Mutant: ~200 bp) were separated on a 1.5% agarose gel.  
Chk2 mice (84) were genotyped using primers WT#1F 5’-GTG TGC GCC 
ACC ACT ATC CTG-3’; WT#2R 5’-CCC TTG GCC ATG TTT CAT CTG-3’ and 
Neop53 5’-TCC TCG TGC TTT ACG GTA TC-3’ following the same condition as 
the Brca1S1598F mice genotyping PCR (WT: 439 bp; Mutant: ~600 bp).  
Primary cell cultures and HDR assays. The tetracycline-inducible I-SceI transgenic 
system was established by Elizabeth Kass in the Jasin lab (39). All experimental mice 
were hemizygous for the Pim1drgfp and CMV-rtTA alleles. The TRE-I-SceI allele was 
also hemizygous, except when labeled as I-SceIS/S to indicate homozygous alleles (all 
I-SceIS/S mice are directly provided by Elizabeth Kass). No significant difference in % 
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GFP+ and % site-loss between hemizygous and homozygous TRE-I-SceI alleles was 
observed in the ex vivo HDR assays in the cohort. 
 Primary ear fibroblasts and MEFs were cultured in DMEM-HG medium 
supplemented with 10% tetracycline-free FBS (Clontech), 1X Pen-Strep, and 1X 
MEM/NEAA. Primary mammary epithelial cells were cultured in DMEM-HG:F12 
medium with 10% tetracycline-free FBS, 1X Pen-Strep, 10 µg/ml insulin and 5 ng/ml 
EGF.  
For ear fibroblast isolation, ear tips are cut from 6- to 8-week-old mice, minced 
with a razor blade, and dissociated in 5 ml serum-free DMEM medium containing 2 
mg/ml collagenase A (Roche) and 1X Pen-Strep on a 37°C shaker for 3 hr. The 
dissociated tissues were passed through a 70-µm strainer, pelleted by centrifugation at 
400 g for 8 min, and plated to 6-well plate for 1-2 days before experiments.  
 For MEF isolation, E12.5-E14.5 mouse embryos were separated from the 
placenta and embryonic sac, then minced following the removal of head and liver, and 
then dissociated in 0.05% trypsin at 37°C for 45 min in a 6-cm dish. The dissociated 
cells were resuspended by pipetting, pelleted at 400 g for 10 min, and plated to a 6-cm 
dish coated with 0.1% gelatin for 1-2 days.  
 For mammary epithelial cell isolation, the 4th inguinal mammary glands from 
8- to 10-week-old virgin female mice were minced and dissociated in 5 ml serum-free 
DMEM-HG:F12 containing 2 mg/ml collagenase A, 5 µg/ml insulin, and 1X Pen-
Strep on a 37°C shaker for 2 hr. The dissociated cells were pelleted at 400 g for 10 
min, resuspended in 6 ml serum-free DMEM-HG:F12 containing 10 µg/ml DNase I 
(Stem Cell Technologies) and inverted for 2 min, and then pelleted again by 
centrifugation. Red blood cells were lysed with ammonium chloride solution (Stem 
Cell Technologies), and the epithelial organoids were separated from other cell types 
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using two sequential short spins (10 and 5 sec) at 400 g, and then plated to 6-well plate 
coated with collagen I for 1 day. 
 For HDR assays, primary fibroblasts and mammary epithelial cells at passage 
one were plated at a density of 105 cells per single well of 6-well plate the night 
before, then treated with 1 µg/ml Dox (Clontech) to induce I-SceI expression. The 
percentage of GFP+ cells was analyzed after 48 hr by flow cytometry. For inhibition of 
ATM, 3 µM KU-55933 (Calbiochem #118502, 10 mM solution) or equal volume of 
DMSO were added together with Dox and replenished at 24 hr. For CHK2 inhibition 
(EMD Millipore #220486), the same procedure is followed. 
 Primary B cells were purified from mouse spleens by CD43 negative selection 
(Miltenyi Biotec 130-049-801) as described (85). The B cells were cultured at a 
density of 106 cells/ml, stimulated with cytokines (10 µg/ml LPS, 2 µg/ml anti-CD40, 
and 25 µg/ml mouse IL4) in combination with 0.25 µg/ml Dox (can even go down to 
0.1 µg/ml). The B220+GFP+ cells were analyzed by flow cytometry at 96 hr.  
Mouse ES cell culture and transfection. The Brca1SF/SF mouse ES cell line carrying 
a Pim1Neo-targeted DR-GFP allele (clone A8) (31) as well as the Ctip+/- and CtipS326A/- 
DR-GFP clones (8) were provided by Thomas Ludwig at Ohio State University and 
subsequently weaned from MEF feeder layers after receiving. Atm-/- (29) and WT J1 
(obtained from mouse targeting facility at MSKCC) ES cell lines were targeted with a 
linearized Pim1Hyg/Puro DR-GFP plasmid using a previously described method (86) to 
one allele of the Pim1 locus on chromosome 17 and confirmed by Southern blotting 
(Appendix Figure A.7). Among the several heterozygous-targeted clones characterized 
for HDR assay (Figure 2.1C), J1 clone 8 and Atm-/- clone 1 showed more consistent 
HDR results and transfection efficiency and thus were used for most experiments. All 
mouse ES cell lines were cultured in DMEM-HG medium supplemented with 12.5% 
stem cell grade FBS (Gemini), 1X Pen-Strep, 1X MEM/NEAA, 1X L-Gln, 833 U/ml 
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LIF (Gemini), and 0.1 mM β-mercaptoethanol. Culture dishes were pre-coated with 
0.1% gelatin. For electroporation, 3-4 × 106 ES cells per 10-cm dish were plated the 
night before. Typically a total of 3 × 106 cells and 30 µg plasmid DNA were used for 
each electroporation. The trypsinized cells were resuspended in 600 µl warm Opti-
MEM, mixed with I-SceI-expressing pCBASce plasmid, and pulsed with a Gene 
Pulser Xcell (Bio-Rad) in a 0.4 cm cuvette at 250 V/950 µF. After pulsing, the cells 
were mixed with growth medium and plated to a 6-cm dish; for ATM inhibition, the 
transfection mixture was split to two wells of a 6-well plate containing ATMi KU-
55933 or equal volume of DMSO, replenished at 24 hr. As a control for transfection 
efficiency, equal amount of pNZ-EGFP plasmid and pCAGGS empty vector were 
electroporated in independent reactions, respectively. Analysis of GFP+ cells by flow 
cytometry was typically performed at the 24-hr time point for mouse ES cells, given 
that the transfection efficiency of pNZ-EGFP plasmid started to drop after 24 hr and 
the levels of % GFP+ HDR usually reached plateau at 48 hr. The average transfection 
efficiency at 24 hr was around 80-90% and the background % GFP+ without I-SceI 
transfection was less than 0.01% for these ES cell clones. Plasmids were prepared 
using PureLink Maxiprep kit (Invitrogen). 
Site-loss PCR assays. Genomic DNA was extracted from primary cells following I-
SceI induction using Gentra Puregene Mouse Tail Kit (Qiagen). The sequence 
spanning the I-SceI cleavage site in the SceGFP gene was amplified from 100 ng of 
genomic DNA using Advantage 2 Polymerase (Clontech) with forward primer dr.for 
5’-CCC GCC ACC TGC CCC ATC TGC TA-3’ and reverse primer dr.rev 5’ -CCT 
CTA CAA ATG TGG TAT GGC TGA TTA TG-3’; this primer set does not amplify 
SSA products. The PCR condition is as follows: 95°C/1 min; 33 cycles of 95°C/15 sec 
and 70°C/2 min; and a final extension of 70°C/5 min. The reaction contains 2% 
DMSO. The PCR products were aliquoted in half and digested with 8 U I-SceI 
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endonuclease (Thermo Fisher Scientific) or buffer-only control in vitro at 37°C 
overnight and separated on a 1% agarose gel. Band intensities were quantified using 
ImageJ. The intensity of the uncut band (0.9 kb) was divided by the sum of the uncut 
(0.9 kb) plus the large cut band (0.7 kb; accounted for the size difference with a 
correction factor 1.3) to calculate % I-SceI site loss. Animals with % site loss smaller 
than 20%, which generally also show lower % GFP+ signal and low I-SceI protein in 
western blot, were considered having inefficient DNA cutting due to low I-SceI 
induction and were usually excluded from the cohort analysis. 
Site-loss PCR could also be performed with the same dr.for forward primer 
with another reverse primer dr.rev3 (5’-GGA CAA ACC ACA ACT AGA ATG CAG 
TG-3’) that gave cleaner background for pCBASce plasmid-transfected samples; the 
amplified product for this primer set was 1.1 kb and the digested products were 0.9 
and 0.2 kb.  
Single-strand annealing PCR. SSA analysis was performed as described (41). 
Briefly, the products of SSA were amplified from 200 ng genomic DNA extracted 
from primary cells following I-SceI induction using PuReTaq PCR beads (GE 
Healthcare) with forward primer SA.F 5’-TTT GGC AAA GAA TTC AGA TCC-3’ 
and reverse primer SA.R2 5’-ATG ACC ATG ATT ACG CCA AG-3’. For 
comparison, the structurally intact SceGFP gene (or one that had undergone HDR or 
NHEJ) was amplified using the same forward primer and a different reverse primer 
SA.R1 5’-CAA ATG TGG TAT GGC TGA TTA TG-3’ from 100 ng genomic DNA. 
The band intensity of SSA product (0.9 kb) was normalized to that of SceGFP (1.1 kb) 
for each sample as an internal control, and the derived ratio of mutants was relative to 
that of control samples on the same gel. This SSA analysis only used control/mutant 
pairs that have similar % I-SceI site loss, i.e., similar DSB efficiency, for relative 
comparison. 
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Cell cycle analysis. Trypsinized cells were resuspended in 300 µl ice-cold PBS, and 
700 µl of ice-cold 100% ethanol was added drop-wise to the cells while vortexing at 
low speed to a final concentration of 70% ethanol. The samples were fixed at -20°C at 
least overnight, then pelleted at 2000 g for 5 min, washed with PBS once, and 
incubated in 200 µl staining solution (25 µg/ml propidium iodide, 0.1 mg/ml RNase A, 
0.05% Triton X-100 in PBS) at 37°C for 30 min followed by flow cytometry. The cell 
cycle distribution was analyzed using FlowJo cell cycle analysis tool. 
Colony formation assay. Mouse ES cells were plated at a density of 1000-1200 cells 
per well in 6-well plates overnight. Cells were pre-treated with 3 µM ATMi KU-
55933 or DMSO for 2 hr, and then treated with PARPi olaparib (synthesized in the 
MSKCC Organic chemistry core facility) in combination with ATMi or DMSO for 48 
hr. All media were added along the wall to avoid disrupting colonies. After removing 
the olaparib-containing medium, the cells were gently washed with PBS once and then 
incubated with medium containing only ATMi or DMSO for another 3-4 days until 
colonies become visible. The colonies were fixed in 100% methanol for 20 min, 
stained in 3% Giemsa for 3-4 hr, and then washed in distilled water. Colony pictures 
were scanned and each experimental set was counted around the same time manually 
using ImageJ. IC50 is plotted by nonlinear regression using Prism 6 software. 
Mammary gland whole mount staining. The 4th inguinal mammary glands from >8-
week-old virgin female mice were harvested and gently spread on microscope slides 
with a sheet of parafilm. The slides were fixed in Carnoy’s fixative (60% ethanol, 30% 
chloroform, and 10% glacial acetic acid) overnight, defatted in acetone for 30 min, 
sequentially washed in 70%/50%/30% ethanol for 15 min each and in distilled water 
for 5 min. The rehydrated slides were incubated in carmine alum solution (2% 
carmine, 5% aluminum potassium sulfate in water) at room temperature (RT) 
overnight. After staining, the slides were dehydrated with sequential washes in 
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70%/95%/100% ethanol for 15 min each, incubated in fresh 100% ethanol for 15 min, 
cleared in CitriSolv (Fisher Scientific) overnight until the fat pads become transparent, 
and sealed in Permount mounting medium (Fisher Scientific) for photography. 
Western blotting. Proliferating cells were scraped from dishes on ice and lysed for 30 
min on ice in TEGN buffer (10 mM Tris, pH 8, 1 mM EDTA, 10% glycerol, 0.5% 
NP-40, and 400 mM NaCl) with freshly added 1 mM DTT and 1X 
protease/phosphatase inhibitor EDTA-free cocktails (Pierce #88669). Lysates were 
centrifuged at 13000 g for 20 min and the supernatant was collected. Protein 
concentration was quantified using Bradford protein assay (Bio-Rad). Typically an 
amount of 30 µg protein was diluted in 1X Blue SDS Loading Buffer (New England 
BioLabs) with 42 mM DTT and boiled at 95°C for 7 min before loading. 53BP1 was 
separated on 3-8% Tris-Acetate gels (Invitrogen) and transferred to a PVDF 
membrane in Tris-Glycine buffer containing 0.01% SDS and 10% methanol at 22V, 
4°C overnight. Blocking was performed in 5% milk diluted in PBST (1X PBS/0.1% 
Tween-20) at RT for 1 hr. Primary antibodies were diluted in 2.5% milk and incubated 
at 4°C overnight on a rotator. HRP-conjugated secondary antibodies (GE Healthcare) 
were diluted 1:10000 in 2.5% milk and incubated at RT for 1 hr on a shaker. Each 
incubation was followed by three 10 min-washes in PBST. The membranes were 
developed using Enhanced ECL reagents (PerkinElmer). Primary antibodies used: 
Anti-53BP1, 1:4000 (Novus NB100-304); Anti-Clathrin heavy chain, 1:10000 (BD 
Biosciences 610500).  
Immunofluorescence staining. Primary ear fibroblasts were plated in 8-well chamber 
slides (BD Falcon; pre-coated with poly-L-lysine) at a density of 2×104 cells per well 
overnight, followed by 10 Gy IR and 2 hr recovery in incubator. Cells were fixed in 
fresh 3% paraformaldehyde/2% sucrose/PBS at RT for 10 min. For RPA foci staining, 
cells were pre-extracted with cold 0.5% Triton X-100/PBS on ice for 5 min and 
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washed once with PBS before fixing; for RAD51 foci staining, cells were washed 
once with PBS and fixed directly without pre-extraction. After fixing, the slides are 
washed with PBS twice, permeabilized in 0.5% Triton X-100/PBS at RT for 10 min, 
and blocked in 1% IgG-free BSA (Jackson ImmunoResearch)/0.1% Triton X-100/PBS 
on a shaker at RT for 30 min. The slides were incubated with primary and secondary 
antibodies diluted in blocking buffer (70 µl/well) at RT on a shaker for 2 and 1 hr, 
respectively. Following each staining step the slides were washed with PBS three 
times, 10 min for each on a shaker. Finally, the slides were fixed in ProLong Gold 
Antifade Mountant with DAPI (Molecular Probes) and analyzed by microscopy. 
Antibodies used: Anti-RAD51, 1:400 (Calbiochem PC130). Anti-RPA2, 1:400 (Cell 
Signaling 2208). Alexa Fluor 488/594-conjugated secondary antibodies, 1:400 
(Molecular Probes). 
Statistical analysis. Statistical comparisons were calculated using two-tailed 
Student’s t-test. All error bars in the figures represent one standard deviation from the 
mean. 
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CHAPTER THREE 
ATM HAS DISTINCT EFFECTS ON HDR MODULATED BY 53BP1 IN 
MOUSE BRCA1 EXON 11-SKIPPING MUTANT CELLS  
 
Abstract 
Mutations across the major domains of BRCA1 are associated with various levels of 
HDR deficiency. Here we genetically dissect how two hypomorphic mutations of 
BRCA1 affect the interplay with ATM and 53BP1 in HDR in mouse ES cells. In a 
Brca1S1598F mutant that disrupts the phosphoprotein-binding BRCT domain at the C 
terminus, ATM activity promotes HDR regardless of 53BP1 status. However, in a 
Brca1ex11 alternative splicing mutant that skips the central region of BRCA1 but 
retains the BRCT domain, whether ATM supports HDR is determined by the status of 
53BP1: Only in the absence of 53BP1 does ATM promote HDR. The Brca1ex11 mutant 
also shows more augmented DNA damage and NHEJ-mediated suppression of HDR 
that correspond to its more severe repair defects. These results demonstrate that 
structural mutations of BRCA1 could differentially affect how ATM participates in 
HDR through a context-dependent regulation by 53BP1. 
 
Introduction 
Many cancer-associated BRCA1 mutations result in frameshift and truncation of the 
protein, although missense mutations also occur throughout different domains of 
BRCA1 protein that could impact its DSB repair and tumor suppression functions (1, 
2). Alternatively spliced transcripts of BRCA1 have also been identified in various 
contexts, including proliferative and tumorigenic tissues as well as normal 
counterparts (3, 4). These alternative splicing events frequently occur around exon 11, 
the largest exon of BRCA1, resulting in various isoforms that lack part of the central 
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region of the BRCA1 protein (3, 5). The significance of the exon 11-encoding region 
is less defined compared to the N and C terminus of BRCA1. This region contains two 
nuclear localization signals, though these are not essential for BRCA1 nuclear import 
(6, 7), and other elements such as interaction sites for DNA and RAD51 as well as 
phosphorylation sites that together contribute to the functions of BRCA1 in DNA 
damage checkpoints and HDR (8-11). BRCA1-mutant breast tumors maintaining an 
isoform that skips most of the exon 11 (Δ11q) show partial resistance to PARPi 
compared to tumors with complete loss of BRCA1 expression (12). This residual 
function of Δ11q is in part dependent on the remaining interaction of the peptide with 
PALB2. Thus, these splicing isoforms of BRCA1 could have a role in therapeutic 
resistance by preserving some levels of DSB repair activity.  
A number of Brca1 exon 11-skipping mouse alleles have been developed 
either by deleting the entire exon 11 via Cre-loxP recombination (referred to below as 
Brca1Δ11) (13) or disrupting the splicing acceptor of exon 11 with a targeting cassette 
(referred to below as Brca1ex11) (14, 15), both producing the exon 11-skipping peptide 
(Δ11) consisting of the N-terminal RING domain fused with the C-terminal coiled-coil 
and BRCT domains. In the presence of full-length BRCA1, this isoform appears to be 
dispensable for mouse development (16). However, mice exclusively expressing the 
BRCA1Δ11 protein show embryonic lethality ranging from mid E9.5-10.5 (14, 15) to 
late E12.5-18 (17) stages depending on the structure of mutant allele, whereas mice 
carrying Brca1 alleles that are considered nullizygous die at an earlier stage between 
E5.5-9.5 (18, 19), suggesting a hypomorphic phenotype for the exon 11-skipping 
mutants. Conditional deletion of Brca1 exon 11 has also been studied, in particular in 
the mouse mammary gland where tumorigenesis has been observed (after one year 
(13)). 
	 78 
Studies have shown that HDR is reduced in both Brca1ex11 and Brca1S1598F 
(SF) mutant ES cells (20-23). Our recent work demonstrates that ATM supports much 
of the residual levels of HDR in Brca1SF BRCT mutant cells, and that loss of ATM 
further compromises the viability of Brca1SF/SF mice (Chapter 2, (24)). Intriguingly, 
this phenotype is distinct from that previously reported with Brca1Δ11 mutant mice 
where Atm deletion restores viability of the animals (25). These two BRCA1 mutant 
proteins have very different structures, in that the BRCA1SF protein is full length 
(although deficient in binding phosphoproteins via the BRCT domain) while the 
BRCA1Δ11 peptide maintains an intact BRCT domain (Figure 3.1A). Although both 
Brca1 mutants have compromised HDR that can be rescued by loss of the resection 
suppressor 53BP1 (24, 26), some aspects of the DNA damage response are different. 
For example, formation of DNA damage-induced BRCA1 foci is impaired upon 
mutation of the mouse S1598 or its human equivalent S1655 (20, 27) but is intact for 
the BRCA1Δ11 isoform (28), likely related to the collaboration of RING and BRCT 
domain functions in BRCA1 chromatin association (29, 30). Particularly striking is the 
contrasting phenotypes in animal viability in the absence of ATM, raising the question 
whether these two BRCA1 hypomorphic mutants differentially affect the interplay 
with other regulators of DSB repair following ATM loss. Here, we show that in mouse 
cells expressing the BRCA1Δ11 splicing isoform, loss of ATM activity has differential 
effects on HDR depending on the status of the NHEJ factor 53BP1: ATM suppresses 
HDR in these cells in the presence of 53BP1 but supports HDR in the absence of 
53BP1. This is distinct from the Brca1SF mutant and WT cells where ATM promotes 
HDR independently of 53BP1. 
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Results 
Derivation of Brca1ex11/ex11 DR-GFP mouse ES cells 
We utilized a mouse Brca1ex11/ex11 ES cell line from Beverly Koller’s lab (UNC) 
carrying a Brca1 allele that has half of exon 11 (encoding amino acid 223-763), 
including the splice acceptor, replaced by a NeoR cassette (15, 23). This integration 
leads to alternative splicing from exons 9 to 12 and the expression of the BRCA1Δ11 
isoform (7). This cell line was previously modified by integrating the DR-GFP 
reporter at the Pim1 locus and shown to be HDR defective (21). A derivative clone 
(#3) of this Brca1ex11/ex11 DR-GFP ES cell line was used for 53bp1 targeting 
experiments (see below), which has the HygR marker gene at the Pim1Drgfp locus 
disrupted by CRISPR/Cas9-mediated mutagenesis to allow for the use of hygromycin-
selection method during gene targeting; the expression of BRCA1Δ11 isoform was 
confirmed by western blotting in this clone #3 before starting the targeting experiment 
(see below, Figure 3.7B). The Brca1SF/SF ES cell line carrying a Pim1-targeted DR-
GFP reporter (clone A8), provided by Thomas Ludwig (OSUCCC), has been 
described in Chapter 2 (20).  
Differential effects of ATM inhibition on HDR in Brca1S1598F and Brca1ex11 cells. 
Because ATM deficiency exacerbates the HDR defects in Brca1SF mutant cells (24), 
we investigated whether ATM inhibition also affects HDR in cells expressing the 
BRCA1Δ11 spliced isoform. Both Brca1SF/SF and Brca1ex11/ex11 ES cells showed an ~8-
fold reduction in HDR 24 hr after transfection of an I-SceI expression plasmid 
compared to a WT J1 ES cell line (Figure 3.1B, left panel). However, unlike 
Brca1SF/SF ES cells, in which treatment with an ATM kinase inhibitor (KU-55933) 
reduced the residual HDR by ~2.6-fold, we found that ATM inhibition actually 
increased HDR by ~1.7-fold in Brca1ex11/ex11 cells (Figure 3.1B, right panel). The  
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Figure 3.1 ATM inhibition suppresses HDR in Brca1SF but increases HDR in 
Brca1ex11 ES cells. 
A. The mouse BRCA1 S1598F protein has a point mutation in the BRCT domain that 
disrupts the interaction with phosphoproteins. The BRCA1 Δ11 spliced isoform skips 
the exon 11-encoding central region but retains the downstream coiled-coil (CC) and 
BRCT domains. Both mutant proteins contain the RING domain at the N terminus. 
NLS: nuclear localization signal. 
B. Both Brca1SF/SF and Brca1ex11/ex11 mouse ES cell lines have severely reduced HDR 
(left). Treatment of an ATMi (3 µM, 24 hr) in Brca1SF/SF cells reduces HDR to a 
greater extent than in WT cells; by contrast, ATMi treatment increases HDR in 
Brca1ex11/ex11 cells (right). All error bars in the figures of this chapter represent one 
standard deviation from the mean. (n=5) 
C. Cell cycle profiles of the Brca1 mutant ES cell lines are not significantly affected 
by ATM inhibition (3 µM, 24 hr) at the time point of HDR analysis. (n≥3) 
D. Unlike in Brca1SF/SF ES cells, continuous treatment with ATMi (3 µM) does not 
further sensitize Brca1ex11/ex11 ES cells to a 48-hr pulsed treatment with olaparib. IC50 
of olaparib with/without ATMi: Brca1SF/SF, 14.5/3.9 nM; Brca1ex11/ex11, 8.9/9.3 nM. 
The fold is relative to the colony number of DMSO-only treatment. (n≥3) 
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Figure 3.1 
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difference was not related to any significant changes in cell cycle profiles (Figure 
3.1C).  
 We also examined the colony formation capability of these Brca1 mutant ES 
cell lines following a 48 hr pulse of different doses of olaparib. Brca1ex11/ex11 ES cells 
showed more sensitivity to olaparib (IC50 8.9 nM) than Brca1SF/SF cells (IC50 14.5 nM) 
(Figure 3.1D). This differential sensitivity to this DNA damaging agent may be related 
to the more severe developmental defects of mice expressing the Δ11 isoform than the 
Brca1SF mutant mice (17, 20). When we combined increasing doses of olaparib with a 
defined dose of the ATMi, colony formation of Brca1SF/SF cells was further suppressed 
compared to olaparib treatment alone (~5-fold reduction at 10 nM olaparib+ATMi 
versus ~1.7-fold reduction at 10 nM olaparib; Figure 3.1D, left panel), whereas the 
olaparib-treated Brca1ex11/ex11 cells did not show any further colony reduction upon 
ATM inhibition (~2-fold reduction at 10 nM olaparib with or without ATMi; Figure 
3.1D, right panel). The IC50 of olaparib in the combination with ATMi for Brca1SF/SF 
cells was thus decreased to 3.9 nM, whereas the IC50 for Brca1ex11/ex11 cells remained 
similar at 9.3 nM. Together, these results suggest that ATM kinase activity supports 
HDR in Brca1SF cells but conversely inhibits HDR in Brca1ex11 cells.  
Mutation of 53bp1 in WT ES cells only moderately increases HDR 
Given the roles of the NHEJ protein 53BP1 in suppressing end resection in different 
contexts, we also examined how loss of 53BP1 impacts HDR in ES cells. To mutate 
the 53bp1 gene, we followed a previously described CRISPR/Cas9 method in the lab 
(31) (see Appendix A.8 for 53bp1 targeting scheme and clonal analysis). Loss of 
53BP1 protein following mutagenesis was confirmed by western blotting (Figure 
3.2A). HDR in the 53bp1-/- clone #26 was increased by ~1.4-fold at 24 hr compared to 
WT ES cells, but the difference was not significant, likely due to the variation of 
transfection efficiency (Figure 3.2A). We also examined HDR at a later time point  
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Figure 3.2 Loss of 53BP1 in the presence of BRCA1 only slightly increases HDR. 
A. Mutation of 53bp1 in WT ES cells slightly increases HDR at 24 hr but this does not 
reach statistical significance. Loss of 53BP1 is confirmed by western blot using a 
Brca1ex11/ex1153bp1-/- clone #60 as a negative control (see below). (n=4) 
B. At 48 hr HDR is slightly higher in 53bp1-/- cells but is not significantly different 
from WT (left). There is also no significant difference when normalizing % GFP+ to % 
I-SceI site-loss despite a ~1.2-fold increase in 53bp1-/- cells (right). (n=4) 
C. 53bp1-/- ES cells respond to treatments with olaparib and/or ATMi similarly to WT 
cells. (n=2 for 100 nM dose) 
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(48 hr) which showed a ~1.3-fold increase in % GFP+ in 53bp1-/- cells, but this again 
did not reach significant difference (Figure 3.2B, left panel). To have a better 
measurement on the fraction of HDR over total repair events, we normalized % GFP+ 
with overall repair efficiency using an I-SceI site loss assay (i.e., % HDR; see Chapter 
2), which confirmed that HDR in 53bp1-/- ES cells had a ~1.2-fold increase compared 
to WT cells (Figure 3.2B, right panel). The small elevation in HDR in 53bp1 mutant 
ES cells is similar to the observation in primary fibroblasts derived from 53bp1-/- mice 
(Chapter 2, (24)), suggesting that loss of 53BP1 in the presence of wild-type BRCA1 
promotes only a moderate increase in HDR. The 53bp1-/- #26 cells also did not show 
any observable reduction in colony numbers upon treatment with olaparib alone, as 
expected, and had only a ~1.2-fold reduction upon the combined treatment with 
olaparib and ATMi, similar to the response in WT ES cells (Figure 3.2C). 
53BP1 modulates the response of Brca1ex11 mutant cells to ATM inhibition.  
53BP1 plays a major role in counteracting BRCA1 and is also regulated by ATM. 
Given the complex interplay of these three proteins in DSB repair, we performed 
mutagenesis of 53bp1 in the two Brca1 mutant ES cell lines to address whether 53BP1 
deficiency affects the distinct HDR responses following ATM inhibition. The 
Brca1ex11/ex11 #3 derivative clone used for 53bp1 mutagenesis showed slightly lower 
baseline HDR (0.13% at 24 hr) than the parental Brca1ex11/ex11 cells (0.21% at 24 hr) 
analyzed previously (Figure 3.1B). When we examined HDR in Brca1ex11/ex1153bp1-/- 
clones #17 and #18, we found that loss of 53BP1 rescued HDR by 4-fold, raising % 
GFP+ from 0.13% to ~0.5% (Figure 3.3A). This was still not comparable to the 1.7% 
in WT J1 cells (Figure 3.1B), but this was likely due to the low levels of baseline 
HDR in this Brca1ex11/ex11 #3 cell line used for 53bp1 mutation. In particular, this 
increase in HDR following 53BP1 loss in Brca1ex11/ex11 cells was enough to 
substantially rescue the olaparib sensitivity, as both Brca1ex11/ex1153bp1-/- clones  
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Figure 3.3 Mutation of 53bp1 in Brca1ex11 cells abolishes the increase in HDR 
triggered by ATM inhibition. 
A. Mutation of 53bp1 rescues the HDR defect in Brcaex11/ex11 ES cells by 4-fold. Two 
independent double mutant clones (#17 and #18) are examined. Loss of 53BP1 is 
confirmed by western blot using 53bp1-/- primary fibroblasts as a control. Brca1ex11/ex11 
#3: a derivative clone of Brca1ex11/ex11 DR-GFP ES cells; this clone has lower baseline 
HDR than the parental cells. (n=5) 
B. Mutation of 53bp1 rescues the HDR defect in Brca1SF/SF ES cells by 4-fold. Two 
independent double mutant clones (#25 and #37) are examined. (n=5) 
C. Mutation of 53bp1 in Brca1ex11/ex11 ES cells abolishes the increase in HDR 
following increasing doses of ATMi treatment (3/10 µM, 24 hr). (n=5) 
D. Mutation of 53bp1 in Brca1SF/SF ES cells attenuates the extent of HDR reduction 
following treatment of ATMi (3 µM, 24 hr). (n=5) 
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showed only a 1.2-fold reduction in colony number even with treatment of 100 nM 
olaparib, at which dose all Brca1ex11/ex11 cells were killed (Figure 3.4A, blue bars 
alone, compare #3 with #17 or #18). These results suggest the exon 11-encoding 
region of BRCA1 is required for counteracting 53BP1 in response to olaparib-induced 
damage (26).  
For the Brca1SF mutant, we found that HDR was rescued by ~3-fold in 
Brca1SF/SF53bp1-/- clone #25 and ~4-fold in clone #37 compared to Brca1SF/SF cells 
(Figure 3.3B). This significantly increased % GFP+ from 0.3% to 1-1.2% (Figure 
3.3B), which became only ~1.4-fold lower than the 1.7% in WT cells (Figure 3.1B). 
The HDR difference between clone #25 and #37 (p=0.04) was likely due to clonal 
variation, which could be followed up in other clones such as #35 (Appendix A.8 F 
and G). Both Brca1SF/SF53bp1-/- clones showed an almost complete rescue of colony 
formation in response to 100 nM olaparib, at which dose 70% of the Brca1SF/SF 
colonies were eliminated (Figure 3.4B, blue bars alone, compare #3 with #25 or #37). 
These results are consistent with the notion that the BRCT domain plays a role in 
counteracting 53BP1 for HDR, as observed in the mouse primary cell experiments 
(Chapter 2, (24)). 
We next examined whether loss of 53BP1 affects the distinct HDR responses 
following ATM inhibition in the Brca1ex11 and Brca1SF mutants. Interestingly, we 
observed that in the Brca1ex11 mutant, the status of 53BP1 controls whether ATM 
promotes HDR. In Brca1ex11/ex11 #3 cells, treatment of ATMi increased HDR by ~1.5-
fold compared to DMSO; however, in Brca1ex11/ex1153bp1-/- clones #17 and #18 
without 53BP1 expression, the rescued HDR was no longer increased by ATMi 
compared to DMSO (Figure 3.3C, 3 µM ATMi). Thus, the HDR increase in 
Brca1ex11/ex11 cells upon ATM inhibition is dependent on 53BP1.  
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Conversely, we found in the Brca1SF mutant that, while ATM inhibition 
reduces HDR, the HDR reduction is not more severe in the absence of 53BP1 but 
rather even somewhat decreased. In Brca1SF/SF cells, treatment of ATMi reduced HDR 
by ~2.5-fold; in Brca1SF/SF53bp1-/- clones #25 and #37, ATMi treatment also reduced 
HDR, although somewhat less, i.e., by ~1.6- and 1.3-fold, respectively (Figure 3.3D). 
This is distinct from the reversed trend in the Brca1ex11 mutant before and after 53bp1 
mutation, as described above (Figure 3.3C). The ~1.6-fold reduction in HDR in ATM-
treated Brca1SF/SF53bp1-/- clone #25 was similar to that in ATMi-treated WT cells 
(Figure 3.1B, right panel), whereas the less reduction in clone #37 may be due to the 
difference in the rescuing effects of 53BP1 loss on the baseline HDR (Figure 3.3B, 
greater rescue in #37 than #25) or other effects from gene targeting, which can be 
addressed with more clonal analysis. Nevertheless, the HDR results in the 
Brca1SF/SF53bp1-/- ES cells were supported by the primary cell data described in 
Chapter 2 that mutation of 53bp1 in Brca1SF/SF ear fibroblasts attenuated the fold of 
HDR reduction from 5-fold to 1.4-fold upon ATM inhibition. Given that BRCA1 is 
especially important for HDR in embryonic cells (Chapter 2), the smaller HDR 
reduction in ATMi-treated Brca1SF/SF53bp1-/- ES cells may also indicate a dependence 
(either direct or indirect) on ATM to counteract 53BP1 in the Brca1SF embryonic 
contexts, whereas such a dependence on ATM is relieved once 53BP1 is lost.  
We also examined the effect of 53BP1 loss in the two Brca1 mutants to 
combined treatment with olaparib and ATMi. In the presence of 53BP1, Brca1ex11/ex11 
#3 cells were sensitive to olaparib, but combined treatment with ATMi did not further 
reduce its colony formation (Figure 3.4A, left panel, compare blue and red bars). 
Following the loss of 53BP1, Brca1ex11/ex1153bp1-/- clones #17 and #18 became 
resistant to olaparib; however, upon the combined treatment with olaparib and ATMi, 
Brca1ex11/ex1153bp1-/- cells now showed a 2-fold reduction in colony formation  
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Figure 3.4 Mutation of 53bp1 in Brca1ex11 cells makes them sensitive to combined 
treatments with olaparib and ATMi. 
A. Brca1ex11/ex1153bp1-/- ES cells are much more resistant to olaparib (48 hr) compared 
to Brca1ex11/ex11 cells. Whereas combined treatment with ATMi (continuous) has no 
effects in Brca1ex11/ex11 cells, it further reduces colony formation in 
Brca1ex11/ex1153bp1-/- cells. (n=3) 
B. Combination of 48-hr olaparib treatment with continuous ATMi treatment reduces 
colony formation in both Brca1SF/SF and Brca1SF/SF53bp1-/- ES cells, though the fold of 
decrease is smaller for the latter one. (n=3)  
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compared to olaparib alone (versus DMSO: 2.5-fold reduction at 100 nM 
olaparib+ATMi, 1.2-fold reduction at 100 nM olaparib; Figure 3.4A, middle and right 
panels, compare blue and red bars). This suggests that in cells expressing the 
BRCA1Δ11 isoform, ATM contributes to HDR in response to olaparib only when 
53BP1 is removed, in agreement with the report that ATM inhibition reduces the 
formation of RAD51 foci in irradiated Brca1Δ11/Δ1153bp1-/- B cells (26). The opposing 
HDR responses to ATM inhibition in the Brca1ex11 mutant before and after 53bp1 
mutation support a modulating role for 53BP1 in this process.  
In the presence of 53BP1, Brca1SF/SF ES cells showed a further reduction in 
colony formation upon the combined treatment with olaparib and ATMi (Figure 3.4B, 
left panel, compare blue and red bars). Following the loss of 53BP1, both 
Brca1SF/SF53bp1-/- clones gained resistance to olaparib; when combining ATMi with 
olaparib, the colony formation of Brca1SF/SF53bp1-/- clones #25 and #37 was still 
reduced by ~1.7- and 1.3-fold, respectively, compared to olaparib treatment alone 
(Figure 3.4B, middle and right panels, compare blue and red bars at 100 nM olaparib). 
This suggests that ATM activity supports HDR in the Brca1SF mutant in both 53BP1-
proficient and -deficient condition, consistent with our analysis in primary cells 
showing that ATM has independent roles in resection and HDR in the Brca1SF-53bp1 
double mutant mice (Chapter 2). To summarize, unlike in Brca1SF mutant cells where 
ATM has a positive role in HDR irrespective of the 53BP1 protein, ATM has 
ambivalent effects on HDR specifically in Brca1ex11 mutant cells that are modulated 
by the status of 53BP1: ATM activity suppresses HDR in the presence of 53BP1 but 
supports HDR in the absence of 53BP1.  
HDR in the Brca1ex11 mutant is highly suppressed by NHEJ signaling.  
To gain more insight into the differential HDR responses, we asked whether ATM-
mediated signaling in response to DSBs differs between the two Brca1 mutants. We  
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Figure 3.5 Brca1ex11 cells accumulate high levels of DNA damage upon olaparib 
treatment due to its HDR defect. 
A. Brca1ex11/ex11 ES cells show higher levels of ATM-dependent phosphorylation of 
CHK2 (observed by mobility shift) than Brca1SF/SF cells following olaparib treatment 
(20 hr). WT cells do not show a CHK2 shift. 
B. Phosphorylation of CHK2 following acute damage by IR is not evidently different 
between Brca1SF and Brca1ex11 mutant cells. Lysates are collected 1 hr after IR. 
ATMi: 5 µM. 
C. The level of γH2AX is significantly increased in olaparib-treated (0.5 µM, 22 hr) 
Brca1ex11/ex11 cells that can be alleviated by combined inhibition of DNA-PKcs (3 µM) 
and ATM (5 µM) activity.   
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found that ATM-dependent phosphorylation on its substrate CHK2, as indicated by 
mobility shifts in western blots, was greater in Brca1ex11/ex11 than Brca1SF/SF ES cells 
following treatment with 0.5 µM olaparib for 20 hr (Figure 3.5A), suggesting a more 
profound DNA damage response. WT ES cells are not sensitive to olaparib and thus 
did not show evidence of CHK2 phosphorylation (Figure 3.5A). The stronger damage 
response is likely related to the lower HDR in the Brca1ex11 mutant that results in 
unresolved olaparib-induced DSBs rather than an intrinsic alteration in ATM activity 
per se, since the phosphorylation of ATM substrates upon acute DNA breaks by IR 
was not so different between the two Brca1 mutants (Figure 3.5B). Consistent with the 
notion that the HDR defect in Brca1ex11 mutant leads to more DSB accumulation, loss 
of 53BP1 in Brca1ex11/ex11 cells greatly dampened CHK2 phosphorylation and γH2AX 
formation following olaparib treatment (Figure 3.5C), in accordance with the rescue of 
HDR (Figure 3.3A). The levels of olaparib-induced γH2AX were also substantially 
lower in Brca1SF/SF than in Brca1ex11/ex11 cells, suggesting the Brca1ex11 mutant is a 
more severe hypomorph (Figure 3.5C).  
 Given that H2AX can be phosphorylated by redundant kinases ATM and 
DNA-PKcs, we treated the cells with a DNA-PKcs inhibitor (NU-7441). Although 
γH2AX is typically promoted by ATM, we found that the elevation of γH2AX in 
olaparib-treated Brca1ex11/ex11 cells was greatly suppressed by inhibition of DNA-PKcs 
but not ATM (Figure 3.5C), indicating particularly high activity of DNA-PKcs at 
breaks in the Brca1ex11 mutant. This may be related to the persistent γH2AX formation 
observed in the developing brain of Brca1Δ11/Δ11 embryos even after ATM loss (25). 
Phosphorylation of CHK2 was not affected by DNA-PKcs inhibition (Figure 3.5C). 
Although ATMi alone had little effect on γH2AX, combined inhibition of ATM and 
DNA-PKcs further abolished the γH2AX signals to the background level (Figure 
3.5C). The reduction in γH2AX by inhibition of ATM and DNA-PKcs could indicate  
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Figure 3.6 HDR in Brca1ex11 cells is significantly promoted by DNA-PKcs 
inhibition. 
A. Treatment of a DNA-PKcs inhibitor (1/3 µM, 24 hr) increases HDR significantly 
more in Brca1ex11/ex11 than Brca1SF/SF or WT ES cells. (n≥3) 
B. Transient inhibition of DNA-PKcs (48 hr) cannot rescue the sensitivity to olaparib 
(48 hr) in both Brca1 mutant ES cells. The two different doses of DNA-PKi are 
independent experiments. (n=2 for 1 µM DNA-PKi) 
C. In WT and Brca1SF/SF ES cells, HDR is supported by ATM and inhibited by DNA-
PKcs, whereas both ATM and DNA-PKcs contribute to HDR suppression in Brca1ex1 
1/ex11 cells. DNA-PKi and ATMi: 3 µM, 24 hr. (n≥3)  
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either the ablation of signaling or the physical repair of breaks, unlike that of 53BP1 
loss which likely reflects repair per se; however, the sensitivity to olaparib in Brca1ex11 
mutant cells still cannot be restored by DNA-PKcs inhibition (see below). 
Suppression of NHEJ components such as Ku or DNA-PKcs has been shown 
to increase HDR and promote the survival of HDR-deficient cells following genotoxic 
damage (32-35). Given the strong DNA damage response and γH2AX accumulation in 
Brca1ex11 mutant that are in part dependent on DNA-PKcs, we examined how 
suppressing NHEJ would affect HDR in the two Brca1 mutants. Interestingly, 
inhibition of DNA-PKcs activity led to a more profound increase in HDR in 
Brca1ex11/ex11 (~4-fold) than in Brca1SF/SF (~1.8-fold) or WT (~1.4-fold) ES cells 
(Figure 3.6A), suggesting that the repair pathway competition from NHEJ is more 
prominent in the Brca1ex11 mutant. Although treatment with the DNA-PKcs inhibitor 
increased % GFP+ in Brca1SF/SF and Brca1ex11/ex11 up to 0.7% and 1.6%, respectively, 
the levels were still not comparable to the 3% in DMSO-treated WT cells (note that 
these few experiments with DNA-PKi had higher levels of baseline HDR than those in 
Figure 3.1B, but since WT and mutants were performed side by side this did not 
influence the interpretation). The HDR increase in Brca1ex11/ex11 cells treated with 
DNA-PKcs inhibitor may also contribute to some degree of the γH2AX reduction in 
response to olaparib (Figure 3.5C), however it is difficult to separate repair from the 
signaling aspects.  
 Despite the increased HDR, we found that DNA-PKcs inhibition in these two 
Brca1 mutant ES cell lines did not lessen the sensitivity to low doses of olaparib 
(Figure 3.6B). This is perhaps analogous to the report that loss of Ku cannot rescue the 
lethality of Brca1Δ11 mutant mice (32), and we suspect one possibility may be the 
alternative NHEJ activity in mouse cells that contributes to the toxic end joining 
events following olaparib-induced damage (36, 37), which will not be suppressed by  
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Figure 3.7 BRCA1 protein in WT and Brca1SF cells shows an IR-induced mobility 
shift mediated by ATM. 
A. Mouse BRCA1 protein contains at least 4 conserved ATM phosphorylation sites 
that correspond to human residues S1387, S1466, and S1524 around the coiled-coil 
domain as well as S1189 in the exon 11-encoding region. 
B. The full-length BRCA1 protein in WT and Brca1SF/SF ES cells, but not Atm-/- cells, 
shows ATM-dependent mobility shift following IR. The BRCA1 Δ11 isoform does 
not show apparent mobility shift after IR despite migrating faster than the full-length 
BRCA1. The samples are separated on a 3-8% Tris-Acetate gradient gel and probed 
with an anti-BRCA1 polyclonal antibody against the N terminus (SantaCruz H-100). 
C. The IR-induced mobility shift of BRCA1 Δ11 protein in Brca1ex11/ex11 #3 cells is 
also not very evident on a 10% Tris-Glycine gel. The samples are probed with an anti-
BRCA1 monoclonal antibody against the N terminus (provided by Samuel Bunting at 
Rutgers University). 
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DNA-PKcs inhibition. We also addressed whether the epistatic relationship of ATM 
and DNA-PKcs in HDR is different between the two Brca1 mutants by combining 
inhibitors targeting either kinase. The results suggest that in Brca1SF/SF and WT ES 
cells, ATM and DNA-PKcs operate separately: ATM promotes HDR whereas DNA-
PKcs suppresses HDR (Figure 3.6C). By contrast, in Brca1ex11/ex11 ES cells, both ATM 
and DNA-PKcs activity lead to the suppression of HDR, with DNA-PKcs being the 
epistatic factor for this suppression (Figure 3.6C). These observations suggest that in 
the Brca1ex11 mutant, the stronger competition from NHEJ stimulated by active DNA 
damage signaling likely plays a major role in its more severe HDR defects compared 
to the Brca1SF mutant. 
 
Discussion 
The study in this chapter uncovers an intriguing phenotype that ATM deficiency leads 
to distinct consequence on HDR depending on different BRCA1 mutations. In the 
Brca1SF mutant expressing a BRCT-defective peptide (20), ATM activity supports 
HDR and this regulation is independent of 53BP1, as in the BRCA1-proficient 
context. This is consistent with the synthetic lethality following ATM loss in 
Brca1SF/SF mice, which can be rescued by 53bp1 deletion that restores the HDR defect 
of Brca1SF but not Atm mutant (Chapter 2, (24)). By contrast, in the Brca1 exon 11-
skipping mutant, ATM has suppressive effects on HDR specifically in the presence of 
53BP1, whereas loss of 53BP1 can restore ATM’s supportive roles in HDR. This 
ambivalent regulation of ATM on HDR resonates with the observation in B cells that 
ATM can either suppress or promote resection of RAG-induced DSBs depending on 
the status of H2AX (38), reflecting the dynamic roles of ATM at DSBs.  
Previous studies have shown that loss of ATM, CHK2, or p53 rescues the 
lethality of Brca1Δ11/Δ11 mice via abolishing apoptosis triggered by excessive DNA 
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damage (17, 25). Intriguingly, ATM loss has stronger rescuing effect than p53 loss on 
the proliferation defect in the developing brain of mice carrying a Brca1ex11 allele 
(together with an exon 5−13 floxed allele) (39), suggesting an involvement of p53-
independent functions of ATM in the phenotype of BRCA1Δ11 mutant. Thus, we 
speculate that in addition to the relief of apoptosis, the distinct HDR response upon 
ATM deficiency may also contribute to the viability restoration in Atm-/-Brca1Δ11/Δ11 
mice (i.e., ATM loss at least does not exacerbate HDR defect in this context in the 
presence of 53BP1). Nevertheless, reports show that the Brca1Δ11/Δ11 mice rescued by 
CHK2 loss are still prone to tumorigenesis, unlike those rescued by 53BP1 loss (25, 
26, 40). This indicates that the requirement for ATM in checkpoints and apoptosis is 
still critical for the maintenance of genome integrity on the organismal level (41). 
Model 1: The unique structure of BRCA1Δ11 protein affects interaction with 
repair proteins. 
We hypothesize that the distinct HDR response in the BRCA1 exon 11-skipping 
mutant could be related to two main possibilities: mutant protein structure or altered 
DNA damage response.  
The first possibility regards the structural difference between BRCA1SF and 
BRCA1Δ11 mutant proteins that influences ATM-dependent regulation and/or 
interaction with repair proteins. Among the mapped ATM phosphorylation sites on 
human BRCA1, at least four residues are conserved in mice and one of them is in the 
exon 11-encoding region (42-44) (Figure 3.7A). The significance of ATM 
phosphorylation on BRCA1-mediated HDR remains to be elucidated. The influence of 
ATM could also come from its downstream effectors, e.g., phosphorylation on 
BRCA1 by CHK2 (human S988 in exon 11-encoding region; also conserved in mice) 
is reported to promote HDR (45, 46). While attempting to address the roles of ATM 
activity in Brca1 mutants, our preliminary results found that mouse BRCA1 protein in 
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WT and Brca1SF/SF ES cells, as expected, undergoes an apparent IR-induced mobility 
shift that could be attenuated by ATM inhibition (Figure 3.7 B and C, full-length 
position). The BRCA1Δ11 isoform also appeared to undergo a mobility shift following 
IR but the change was much less pronounced (Figure 3.7 B and C, Δ11 position) (28). 
BRCA1Δ11 isoform still contains some ATM phosphorylation sites (Figure 3.7A) but 
is reported to lack a putative ATM-interacting region located within the exon 11-
encoding region, however this needs to be further studied (43). It is plausible that 
some alterations of post-translational modification or interaction may contribute to a 
different interplay with ATM and 53BP1 at breaks. For example, ATM activity could 
be supporting the hypomorphic functions of BRCA1SF in antagonizing 53BP1, 
resulting in the dependence on ATM for residual HDR; however, such signaling 
crosstalk with ATM may be lacking for BRCA1Δ11, thus leading to more severe 
defects, as reflected on the inviability of Brca1Δ11/Δ11 mice in 53bp1+/+ condition, but 
no further HDR reduction upon ATM loss (as in olaparib sensitivity assay, Figure 
3.4A). Given that BRCA1Δ11 can localize to chromatin (28), the presence of this 
structurally distinct mutant may also interfere with repair dynamics or have 
unidentified biological effects, as observed for another human BRCA1 isoform IRIS 
(terminate in the intron downstream of exon 11) in stimulating DNA replication (47). 
For example, perhaps BRCA1Δ11 can promote ATM and/or DNA-PKcs activity 
through the interaction of BRCT domain with the BAAT1 protein (48, 49), but it lacks 
certain feedback regulation to attenuate the signaling. Furthermore, recent studies 
show that BRCA1 is capable of forming dimers or higher order structures via the 
BRCA1-A (Abraxas) complex assembly (50, 51),	raising the question that if this 
molecular interaction is preserved for the BRCA1Δ11 protein that may in turn affect the 
regulation of the Abraxas/RAP80 complex on chromatin binding and end resection. 
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Model 2: Excessive DNA damage signaling in BRCA1Δ11 mutant affects ATM-
53BP1 interplay and repair pathway antagonism.  
Alternatively, we propose a model that the unique interplay between ATM and 53BP1 
in the BRCA1Δ11 mutant arises from excessive levels of DNA damage signaling that 
further exacerbates the deficiency in repair pathway antagonism, thus contributing to 
the different phenotype from the BRCA1SF mutant. Specifically, we found that 
Brca1ex11/ex11 cells display highly elevated DNA damage response mediated by ATM 
and DNA-PKcs following DSB accumulation compared to Brca1SF/SF cells. This is in 
part due to the more severe repair defect of BRCA1Δ11 mutant protein, which can be 
rescued by 53BP1 loss (Figure 3.5C), but may also be caused by other unidentified 
mechanisms (e.g., the aforementioned protein structure model). The elevated DNA 
damage signaling in the BRCA1Δ11 mutant presumably acts as a safeguard to stop cell 
cycle progression, but it could also have a consequence in the regulation of DSB repair 
pathway choice. For example, given that both ATM and DNA-PKcs phosphorylate 
53BP1 and H2AX (52-54), this may promote higher level of 53BP1 function and/or 
recruitment at breaks that further suppresses the residual HDR. High DNA-PK activity 
may also promote more NHEJ that can compete with HDR (55) (Figure 3.6A). 
Therefore, in the presence of 53BP1, HDR in the BRCA1Δ11 mutant becomes strongly 
suppressed by this signaling amplification, i.e., in this context, ATM has more 
involvement in 53BP1-mediated HDR suppression than HDR promotion (Figure 
3.8A). This leads to genome instability during embryonic development that in turn 
triggers ATM/p53-mediated apoptosis and animal lethality. This helps explain our 
observations that HDR is increased in Brca1ex11/ex11 cells following ATM inhibition 
(Figure 3.3C) as well as the rescue of animal lethality by Atm mutation (25), since the 
suppression on HDR by the ATM-53BP1 pathway becomes relieved. Our results also 
suggest that DNA-PKcs is highly active in Brca1ex11/ex11 cells and appears to be the  
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Figure 3.8 Model: ATM-53BP1 interplay contributes to the severe phenotype in 
Brca1Δ11 mutant mice. 
A. We propose a model that the high levels of DNA damage response in the Brca1Δ11 
mutant leads to a signaling crosstalk between ATM and 53BP1 at breaks. This ATM-
53BP1 interplay exacerbates the imbalance of NHEJ-HDR pathway antagonism and in 
turn causes animal lethality, apart from ATM’s function in triggering apoptosis. See 
discussion for details. 
B. Loss of ATM, 53BP1, or p53 relieves the negative regulation on HDR and viability 
in Brca1Δ11 mutant mice. In particular, following loss of 53BP1, the signaling 
amplification due to HDR deficiency is abolished and the repair aspect of ATM 
activity now only contributes to end resection, thus ATM resumes its positive role in 
HDR.  
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predominant kinase at breaks, whose inhibition causes an even higher increase in HDR 
than ATM inhibition (Figure 3.6C). Overall, this supports the notion that the robust 
DNA damage signaling in the BRCA1Δ11 mutant following DSBs leads to a severe 
imbalance of NHEJ-mediated antagonism against HDR. 
On the other hand, whereas loss of 53BP1 rescues HDR defect in Brca1ex11/ex11 
cells, ATM inhibition in Brca1ex11/ex1153bp1-/- cells starts to reduce HDR and augment 
olaparib sensitivity (Figures 3.3C and 3.4A). This is consistent with the report of 
Bunting et al. that HDR in Brca1Δ11/Δ1153bp1-/- B cells is dependent on ATM and that 
ATM inhibition increases PARPi sensitivity in Brca1Δ11/Δ1153bp1-/- but not no much in 
Brca1Δ11/Δ11 (p53-/-) B cells (see Figure 5 in reference (26)). Loss of 53BP1 in 
BRCA1Δ11 mutant restores HDR in the first place that eliminates DSB accumulation 
and the amplification DNA damage signaling. Furthermore, in the absence of 53BP1 
protein at breaks, we think the repair aspect of ATM activity now mainly contributes 
to end resection factors. Thus, these results probably reflect a shift in the balance of 
ATM function from 53BP1-mediated NHEJ towards HDR following 53BP1 loss in 
the BRCA1Δ11 mutant (Figure 3.8B).  
 
Methods 
Mouse ES cell culture and transfection. Brca1ex11/ex11 (half of exon 11 including 
splice acceptor replaced by a NeoR cassette; also known as Brca1Δ223-763 (23)) ES cell 
line was previously integrated with a Pim1Hyg/Puro DR-GFP allele by Mary Ellen 
Moynahan in the lab (21). Brca1SF/SF (20) (DR-GFP clone A8) and WT J1 (DR-GFP 
clone 8) ES cell lines as well as general culture conditions were described in Chapter 2 
methods. Typically a total of 3-3.5 × 106 cells and 30 µg plasmid DNA were used for 
each electroporation, which was enough to be split to 3-4 treatment conditions in 6-
well plate. The trypsinized cells were resuspended in 600 µl Opti-MEM, mixed with 
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pCBASce plasmid, and pulsed in a 0.4 cm cuvette at 250 V / 950 µF (sometimes 
lowered to 230 V / 950 µF when more cell death occurred after pulsing). After 
pulsing, the cells were mixed with warm growth medium and equally split for 
different treatments in 6-well plate. For ATM inhibition, the transfection mixture was 
split to wells containing the ATMi KU-55933 (Calbiochem #118502, 10 mM solution) 
or equal volume of DMSO, replenished every 24 hr if doing long treatments. For 
DNA-PKcs inhibition, the DNA-PKi NU-7441 (Tocris #3712) was used.  
Mutagenesis of mouse 53bp1. The method of disrupting mouse 53bp1 gene was 
previously described (31). Briefly, a DSB was introduced in 53bp1 exon 2 by 
CRISPR/Cas9 to facilitate the replacement of exon 2 with a promoter-less HygR or 
NeoR cassette by HDR. Sequence of 53bp1 gRNA1:  5’-GAC CCT ACT GGA AGT 
CAA T-3’ (19 bp, PAM is not listed). A total 4 × 106 early-passaging cells were 
electroporated at 250V / 950µF with 10 µg CAGGS-Cas9 plasmid, 10 µg gRNA 
plasmid, and 20 µg of exon 2 targeting template (circular form). After 48 hr, cells 
were replated at a density of 5 × 105 cells per 10-cm dish (3-5 dishes total) and 
selected either in 120 µg/ml Hygromycin B Gold (InvivoGen) or 400 µg/ml G418 
(Gibco) for ~1 week until the colonies became visible for picking. After the clones 
became confluent in 96-well plate, they were trypsinized in 30 µl trypsin, and 10 µl of 
the cell suspension was transferred to a new 24- or 12-well plate whereas 10 µl was 
mixed with 30 µl 1X cell lysis buffer (10 mM Tris pH 8, 0.45% NP40, 0.45% Tween 
20, and 100 µg/ml fresh Proteinase K). The mixture were incubated at 55°C for 2 hr 
and then 95°C for 5 min to inactivate the Proteinase K, and the cell lysates can be 
directly used for PCR genotyping (typically using 1 µl per reaction) or stored at -20°C. 
The targeted clones were initially screened using primers amplifying across 
exon 2 within both homology arms (Universal-F: 5’-CTG AGA AAG TGC TAA 
GAG CG-3’; Universal-R: 5’-ACC TTT CTG TGG GTG AGA AC-3’) and primers 
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amplifying from the inside of left homology arm to the outside of right homology arm 
(Universal-F: see above; Check-3R: 5’-CAT CCT GAT ATG CAT AAG ACA CTG-
3’). The first primer set (internal PCR) had better amplification efficiency than the 
latter one (In-Out PCR). Clones showing the 53bp1 exon 2 potentially with targeting 
cassette integration or with band shifts indicating indels following gRNA cutting were 
subjected to western blotting directly to examine the status of 53BP1 protein 
expression. Mutation of 53bp1 was performed in a Brca1ex11/ex11 clone #3 previously 
established by Yu Zhang in the lab that had undergone a first round of CRISPR/Cas9-
medated mutagenesis to disrupt a HygR marker gene at the Pim1Drgfp allele to allow for 
the use of HygR selection method. Mutation of 53bp1 in Brca1SF/SF cells was 
performed in the DR-GFP clone A8. Mutation of 53bp1 in WT cells was performed in 
the J1 DR-GFP clone 8. The targeting experiments and screening processes were 
performed with the assistance of a volunteering student Megan Mandile in the lab. 
Colony formation assay. Mouse ES cells were plated at a density of 1000 cells per 
well in 6-well plates overnight. For combination with ATMi, cells were pre-treated 
with 3 µM ATMi or DMSO for 2 hr, and then treated with olaparib in combination 
with ATMi or equal amount of DMSO for 48 hr. After that, the cells were gently 
washed with PBS once and then incubated with medium containing only ATMi or 
DMSO for another 3-4 days until colonies become visible. The colonies were fixed in 
100% methanol for 20 min and then stained in 3% Giemsa for 3-4 hr. For combination 
with the DNA-PK inhibitor NU-7441, cells were treated with olaparib in combination 
with DNA-PKi or equal amount of DMSO for 48 hr, then washed and changed to 
blank growth medium for another 3-4 days. Longer incubation (>48 hr) or higher 
doses of DNA-PKi NU-7441 (>1 µM) has suppressive effects on the general growth of 
mouse ES cells. 
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Western blotting. Proliferating cells were scraped from dishes and lysed for 30 min 
on ice in TEGN buffer with freshly added 1 mM DTT and 1X protease/phosphatase 
inhibitors. Lysates were centrifuged and the supernatant was collected. See also 
Chapter 2 methods. Typically an amount of 30 µg protein was loaded for each lane. 
BRCA1 and 53BP1 were separated on 3-8% Tris-Acetate gels (Invitrogen) and 
transferred to a PVDF membrane in Tris-Glycine buffer (25 mM Tris, 192 mM 
glycine) containing 0.01% SDS and 10% methanol at 22 V, 4°C overnight. γH2AX 
was separated on 4-20% Tris-Glycine eXtended gels (Bio-Rad) and transferred to 
PVDF membrane in Tris-Glycine buffer containing 20% methanol at 90 V, room 
temperature (RT) 1 hr. Blocking was performed in 5% non-fat milk in PBST at RT for 
1 hr. Primary antibodies were diluted in 2.5% milk or 5% BSA (when mentioned) and 
incubated at 4°C overnight on a rotator. HRP-conjugated secondary antibodies were 
diluted 1:10000 in 2.5% milk and incubated at RT for 1 hr on a shaker. Each 
incubation was followed by three 10-min washes in PBST. Primary antibodies used: 
Anti-53BP1, 1:4000 (Novus NB100-304); Anti-BRCA1, polyclonal 1:1000 in 5% 
BSA (Santa Cruz H-100 sc7867, lot # D280, discontinued; epitope human BRCA1 
amino acids 1-100) or monoclonal 1:500 in 5% BSA (provided by Samuel Bunting at 
Rutgers University; epitope mouse BRCA1 amino acids 160-300); Anti-CHK2: 
1:1000 (Millipore 05-649); Anti-γH2AX-Ser139: 1:750 in 5% BSA (Millipore 05-
636); Anti-KAP1-pSer824: 1:2000 (Bethyl Laboratories A300-767A); Anti-Clathrin 
heavy chain, 1:10000 (BD Biosciences 610500); Anti-α-Tubulin: 1:10000 (Sigma 
T9026). 
Statistical analysis. Statistical comparisons were calculated using two-tailed 
Student’s t-test. All error bars in figures represent one standard deviation from the 
mean. 
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CHAPTER FOUR 
DISCUSSION AND CONCLUSION 
 
The concept of synthetic lethality has been widely recognized in the development of 
targeted therapies against HDR-deficient tumors. Elucidating the molecular 
mechanisms of HDR not only helps us understand how cells maintain genome 
integrity but can also identify more druggable targets for treatment of cancers and 
related genetic disorders such as Fanconi anemia. In this study, we focus on three key 
regulators in the early steps of DSB repair: ATM, BRCA1, and 53BP1, and address 
how their genetic interaction influences DSB repair pathway choice, in particular 
HDR.  
Our work provides evidence that ATM has a context-dependent role in HDR. 
Loss of ATM in mouse primary cells leads to a moderate reduction in HDR, whereas 
its deficiency causes a delayed HDR response upon I-SceI-induced DSBs in mouse ES 
cells, possibly related to certain properties of ES cells (see discussion in Chapter 2). 
We consider ATM as a minor pathway for end resection and HDR in BRCA1-
proficient cells that can operate independently of the BRCA1-53BP1 antagonism. 
Intriguingly, our genetic analysis shows that the regulation of ATM on HDR can be 
differentially affected by BRCA1 hypomorphic mutations (Figure 4.1). In the context 
of a breast cancer-derived BRCA1S1598F mutation in the BRCT domain, ATM becomes 
essential for supporting the residual HDR and viability, and this positive contribution 
of ATM to HDR is independent of 53BP1. This is distinct from the phenotype of a 
BRCA1Δ11 splicing isoform skipping the exon 11-encoding region, where ATM shows 
opposing effects on HDR that are modulated by the status of 53BP1, i.e., ATM 
promotes HDR only in the absence of 53BP1 in mutant cells expressing the BRCA1Δ11  
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Figure 4.1 Mutations in the BRCT domain and central region of BRCA1 
differentially affect how ATM participates in HDR in mice. 
In Brca1+/+ cells (top), BRCA1 has an essential role in HDR via counteracting 53BP1 
in S/G2 phases. ATM acts as a minor pathway for HDR but also contributes to 53BP1 
function in G1 phase. Both BRCA1SF and BRCA1Δ11 mutants have compromised 
HDR and are defective in counteracting 53BP1. In Brca1SF/SF cells (middle), ATM 
becomes crucial for supporting the residual HDR and this process is independent of 
53BP1. In Brca1ex11/ex11 cells (bottom), HDR is suppressed by ATM activity and 
NHEJ-mediated competition in the presence of 53BP1, whereas loss of 53BP1 allows 
ATM to resume the supporting role in HDR.  
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isoform. Our observations demonstrate how mutations on different domains of 
BRCA1 could drastically change the interplay of HDR and NHEJ pathways, providing 
clinical implications such as targeting BRCA1 tumors carrying BRCT mutations 
specifically with the combination of ATMi and PARPi to achieve better efficacy.  
Potential mechanisms for the synthetic lethality of Atm-Brca1SF double mutant 
Given that HDR is essential for maintaining genome stability during embryonic 
development and that ATM activity supports the residual end resection (HDR and 
SSA) in Brca1SF/SF cells, we think the most plausible explanation for the synthetic 
lethality is an exacerbated defect in HDR proficiency that compromises 
embryogenesis. Strong support for this notion is the rescue of animal lethality by 
homozygous and even heterozygous mutation of 53bp1, which correspond to the full 
and partial HDR restoration in Brca1SF/SF53bp1-/- and Brca1SF/SF53bp1+/- cells, 
respectively. In addition to HDR, BRCA1 participates in the protection of stalled 
replication forks and interstrand crosslink (ICL) repair (1-3). Because recent studies 
suggest that fork protection is not essential for viability (4) and that 53BP1 loss does 
not rescue the defects in fork protection and ICL repair in BRCA1 mutant cells (2, 5), 
we think HDR plays an important role in the Atm-Brca1SF lethality. We also think the 
lethality is not likely caused by the lack of ATM-mediated regulation of DNA damage 
checkpoints and apoptosis, because loss of CHK2 does not lead to synthetic lethality 
and CHK2 inhibition does not reduce HDR to the significant extent as ATM inhibition 
in the Brca1SF mutant. In fact, heterozygosity of Atm (and Chk2) partially rescues the 
sub-viability of Brca1SF/SF single mutant, which is contrary to the lethality with 
homozygous mutation of Atm in the Brca1SF/SF mutant. These observations suggest 
that the Atm-Brca1SF synthetic lethality is likely related to apoptosis-independent 
functions of ATM. 
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We think there are several possibilities regarding why the BRCA1SF BRCT 
mutation shows synthetic lethality with ATM deficiency. First, the Brca1SF mutant 
may be relying on ATM for regulation of end resection. The BRCT domain of 
BRCA1 binds to a number of repair proteins including Abraxas, BRIP1, CtIP, ATRIP, 
and BAAT1 (reviewed in (6)); it also binds DNA-PKcs in a phospho-independent 
manner (7). The interaction of BRCA1 with CtIP and Abraxas is reported to help 
modulate the extent of end resection (8-10). A similar role for ATM in fine-tuning 
resection is also proposed (11-13). As the loss of binding with CtIP alone does not 
recapitulate the Brca1SF phenotype (14, 15), it will be important to determine if loss of 
interaction with either a specific or combination of factor(s), e.g., Abraxas, contributes 
to a dependence on ATM to control the length of resected DNA. Given the consensus 
phosphorylation site (pSer-Pro) in the BRCT-binding motif of these repair proteins 
(6), it will also be interesting to know if certain responsible kinases are involved in 
this HDR regulation. 
Second, phosphorylation by ATM may be directly affecting the functions of 
BRCA1SF protein. Mutation of the ATM phosphorylation site on BRCA1 alone or in 
combination results in phenotypes such as mammary gland abnormalities and 
radiosensitivity in mice as well as failure to support viability in mouse ES cells (16, 
17). However, it is still unclear if ATM-mediated phosphorylation directly regulates 
the functions of BRCA1 in repair pathway choice, as it does on 53BP1 for recruiting 
RIF1 and PTIP. For example, it is possible that ATM-mediated phosphorylation is 
dispensable for BRCA1 WT protein in the antagonism against 53BP1, as the HDR 
defect of Atm mutant is not affected by 53BP1 loss; however, the phosphorylation may 
have a role in supporting the hypomorphic BRCA1SF protein physically counteract 
53BP1, e.g., in 53BP1 spatial reposition (18). This can be addressed by 
complementing with BRCA1 carrying mutations on ATM phosphorylation sites.  
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Third, we consider the possibility that other functions of the BRCA1 BRCT 
domain contribute to the synthetic defect. Studies have shown that the C terminus of 
BRCA1 contains transactivation activity and can interact with transcription 
coactivators such as CBP/p300 or with RNA polymerase II holoenzyme (19-23). It 
will be interesting to determine if ATM has a role in compensating for this regulation 
in the Brca1SF mutant, whose human equivalent S1655F is shown to be defective in 
the transactivation activity (24). Given that BRCT domain mutations (including 
human S1655F) impact BRCA1 peptide folding (24), the potential effects of BRCA1SF 
protein instability on HDR can also be examined, e.g., by comparing the inhibition of 
the proteasome versus heat shock proteins. In addition, recent studies suggest that 
BRCA1 suppresses tumor formation in part via regulating anti-oxidant signaling and 
metabolism (25-27). For example, the BRCT domain of BRCA1 binds and suppresses 
the acetyl-CoA carboxylase 1, which is linked to lipid anabolism in cancer (28-30). 
Given the critical function of ATM in cellular redox homeostasis (31), it will be worth 
knowing whether oxidative stress also plays a part in the synthetic lethality of Atm-
Brca1SF mice , as reported in the Atm-H2ax mice (32). 
Potential mechanisms for the distinct HDR response to ATM deficiency in the 
BRCA1Δ11 mutant 
As discussed extensively in Chapter 3, we propose that the distinct HDR response in 
the BRCA1 exon 11-skipping mutant upon ATM deficiency may be caused by a more 
pronounced DNA damage response due to less efficient repair that affects the ATM-
53BP1 interplay. Alternatively, it could be caused by the specific structure of this 
isoform disrupting repair at DSB sites. The exon 11-encoding region of BRCA1 
interacts with RAD51, and recent studies suggest that the complex formation of 
BRCA1 with BARD1, which also has RAD51-binding ability, can stimulate RAD51-
mediated strand exchange in vitro (33, 34). However, given that both the BRCA1Δ11 
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and BRCA1SF proteins retain the BARD1-binding RING domain and that the HDR 
defect in both mutants is rescued to a similar extent by 53BP1 loss in ES cells, we 
think the presumed loss of interaction with RAD51 in the BRCA1Δ11 mutant is not 
relevant to the different HDR phenotype upon ATM inhibition. The exon 11-encoding 
region has also been shown to possess DNA binding ability (35), but specific deletion 
of this region does not appear to have a strong impact on HDR (36). Another study has 
shown that the BRCA1-Abraxas complex mediates PARylation in the DNA-binding 
region of BRCA1 to control HDR (37); however, if this is the case, both BRCA1SF 
(lacking Abraxas binding) and BRCA1Δ11 (lacking PARylation sites) would be 
predicted to have similar defective phenotypes. Thus, lacking the DNA-binding 
function is not likely the main cause for the distinct response to ATMi in BRCA1Δ11 
mutant. 
Here we discuss several directions that potentially address the distinct HDR 
response in the BRCA1Δ11 mutant, in particular focusing on 53BP1 regulation and 
BRCT domain-related functions of BRCA1 such as chromatin localization and 
resection. First, because 53BP1 has opposing effects on how ATM activity affects 
HDR, we think the priority is to examine if there is any difference in the regulation of 
ATM-53BP1 pathway. This should preferably be done using an isogenic system to 
analyze the phenotypes of different BRCA1 mutations under the same cellular context. 
It will be important to compare the two BRCA1 mutants for the status of 53BP1 
chromatin association, levels of ATM-mediated phosphorylation, and RIF1/PTIP 
recruitment at breaks with and without ATM deficiency. The physical interaction 
between ATM, BRCA1, and 53BP1 proteins before and after damage can also be 
examined. Given that Ku-mediated antagonism of HDR is separated from that of 
53BP1 (2), we should compare if there is a difference in NHEJ activity per se and the 
regulation of Ku and DNA-PKcs (e.g., recruitment and autophosphorylation) to 
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understand why DNA-PK is particularly active at breaks in the BRCA1Δ11 mutant. 
Because our model proposes that a high DNA damage response participates in the 
ATM-53BP1 interplay, it will also be interesting to know if the HDR phenotype is 
changed in a p53-deficient background. 
Second, the localization of BRCA1Δ11 mutant protein to DSB sites may affect 
repair dynamics or interplay with other proteins. Unlike the BRCA1SF mutant (38), the 
BRCA1Δ11 isoform is expressed at comparable levels as WT BRCA1 and has normal 
formation of damage foci following DSBs (39, 40). However, this mutant clearly has a 
more severe impact on HDR and viability than BRCA1SF. As studies on kinase-dead 
mutants of ATM and DNA-PKcs demonstrate that the recruitment of an inactive 
protein to breaks results in more severe phenotypes than the absence of protein (41-
43), we are interested in knowing if the localization of BRCA1Δ11 mutant protein to 
DSB sites somehow alters the functions of other repair proteins including ATM and 
53BP1. Given that the BRCT and RING domains help mediate BRCA1 localization, 
mutations can be introduced in these regions of BRCA1Δ11 to examine the effects on 
HDR; alternatively, H2AX can be mutated to disrupt BRCT-dependent recruitment of 
BRCA1 (44). 
Third, the distinct HDR response may arise from residual regulation of end 
resection mediated by the intact BRCT domain of BRCA1Δ11 protein. Both the 
BRCA1SF and BRCA1Δ11 mutants have reduced HDR and SSA, indicating impaired 
end resection (14, 45). The main cause of this defect is likely the loss of antagonism 
against 53BP1, but there may also be difference in the resection regulation between 
the two BRCA1 mutants, leading to distinct responses to ATM inhibition. For 
example, because the BRCT domain of BRCA1Δ11 presumably still binds Abraxas and 
CtIP, this may reduce the requirement for ATM in supporting resection and also 
contribute to the limited increase in HDR observed following ATM inhibition, as 
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opposed to that in BRCA1SF lacking this interaction. This can be addressed by 
specifically disrupting the BRCT domain in the BRCA1Δ11 protein to examine the 
interplay with Abraxas and CtIP upon DSBs. A physical end resection assay can also 
help elucidate any difference between the two BRCA1 mutants. 
Concluding remarks 
The functions of ATM, BRCA1, and 53BP1 in the maintenance of genome integrity 
have been widely studied since their discovery. However, the data presented in this 
work demonstrate that more needs to be done to elucidate the complex genetic 
interaction between these critical players in DSB repair. Future work is also needed to 
extend the significance of this study to a human context such as breast and ovarian 
cancers. For the therapeutic perspective, our study highlights the importance of 
identifying the mutation spectrum of DSB repair genes in patients and considering 
how they potentially impact protein interactions that could alter the response to 
chemotherapies and development of resistance mechanisms.    
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APPENDIX 
 
Figure A.1 Supporting data of Atm-Brca1SF-53bp1 mutant mice. 
A. Dead Atm-/-Brca1SF/SF mouse can be found at birth and is smaller than the other 6 
littermates, which include control and Atm or Brca1SF single mutants and all are alive 
at birth (left). This litter is from a F3 backcross cage of Atm-Brca1SF mice with 
129/SvJ mice. The same double mutant is also compared to a Brca1SF/SF single mutant 
dead pup from a different cage (right). 
B. Both Atm-/-	and	Brca1SF/SF MEFs are more sensitive to olaparib than control MEFs 
in MTT assay in the absence of ATMi (n≥5). The similar olaparib sensitivity between 
these two mutants resembles that of ES cells in colony assays and different from the 
results that Brca1SF/SF MEFs have more HDR reduction than Atm-/- MEFs (Chapter 2), 
suggesting ATM is particularly required for the repair of olaparib-induced damage. To 
measure cell growth using Vybrant MTT Kit, MEFs are plated in 96-well plates (4000 
cells/well) overnight and treated with olaparib continuously for 5 days, replenished 
once after 2 days. The cells are pulsed with 1.1 mM MTT for 4 hr, lysed in 0.05% 
SDS/HCl for 18 hr, and measured absorbance at OD 570 nM.  
C. Mutations of Brca1SF and/or 53bp1 do not significantly affect the survival of Atm-/- 
mice, the majority of which die around age 3-4 months: 68 out of 72 dissected mice 
carrying Atm-/- genotype, regardless of the Brca1SF-53bp1 status, have enlarged 
thymus indicating thymic lymphoma; 3 other mice without thymic lymphoma have 
tumors at neck, liver, and inguinal mammary gland, respectively. 53bp1-/- single 
mutant can live over one year: 3 out of 6 dead 53bp1-/- mice are dissected and do not 
show signs of thymic lymphoma. Although loss of 53bp1 is reported to accelerate 
lymphoid malignancy in Atm-/- mice on the 129/Sv background (Rybanska-Spaeder et 
al., 2013), we do not see such difference in our colony under mixed backgrounds (blue 
versus green curve). Mice in this cohort carry the combination of DR-GFP and/or I-
SceI/CMV-rtTA alleles. Median survival days: Atm-/- 102; Atm-/- 53bp1+/- 155; Atm-/- 
53bp1-/- 123; Atm-/- Br1SF/SF 53bp1+/- 103; Atm-/- Br1SF/SF 53bp1-/- 123; 53bp1-/- 495.  
D. Most mutant ear fibroblasts have a similar ~20% reduction in cell proliferation 
compared to WT (n≥3), except Atm-/-Brca1SF/SF53bp1+/- which shows a more severe 
~40% reduction (n=2). Primary ear fibroblasts are plated in 12-well plates (4×104 
cells/well) in duplicates overnight. Cell number is counted on hemocytometer on the 
next day and again after 2 days. The 48-hr cell number is normalized to the starting 
number to obtain a 48-hr growth ratio, which is then normalized to the WT in each 
experiment to account for the variation of each harvest. 
E. 53BP1 loss restores the number of IR-induced nuclear RPA foci in Brca1SF and 
Atm mutants (blue lines) to the similar level as WT cells. However, unlike in Brca1SF, 
recombination (e.g., RAD51 foci, DR-GFP) cannot be rescued in the Atm mutant by 
53BP1 loss (Chapter 2). Each genotype consists of at least 3 mice, each with ~30-50 
nuclei counted for the number of RPA foci following IR. Data are graphed using 
Tukey blot with median indicated by the horizontal line in the box.   
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Figure A.1 
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Figure A.1 (Continued) 
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Figure A.2 Genetic interaction of Atm and Brca1tr mutations. 
A. Comparison of mouse WT BRCA1 with S1598F, Δ11, and tr mutant proteins. The 
Brca1tr allele (Ludwig et al., 2001) has sequence insertion in the middle of exon 11 
that results in frameshift and stop codon at the downstream sequence. This is predicted 
to express a BRCA1tr protein truncated after the first 924 amino acids, retaining ~60% 
of exon 11 region while lacking the C-terminal coiled-coil and BRCT domains. This 
Brca1tr allele mimics a breast cancer founder mutation 2800delAA. 
B. The ratio of Brca1tr/tr mice is lower than the Mendelian frequency but can be 
rescued by Atm heterozygosity, which is likely related to the functions of ATM in 
checkpoints. However, viable Atm-/-Brca1tr/tr double mutant mice are not recovered at 
weaning except for one animal, suggesting complete loss of ATM further 
compromises Brca1tr/tr animal viability. The double mutant mouse is smaller than 
littermates (shown in the photo, no weight measurement) and died after 99 days, but 
the cause is uncertain due to festered carcass. The contrasting phenotypes of Atm+/- 
versus Atm-/- in Brca1tr mice have similarity with that of Brca1SF mice, suggesting the 
Brca1tr mutation may have partial synthetic lethality with ATM deficiency. 
C. Atm-/-Brca1tr/tr double mutant embryo can be found at mid-embryogenesis (E12.5) 
and appears smaller than Brca1tr/+ or Atm-/- littermate embryos but grossly normal 
with visible heartbeats. Unlike Brca1SF, MEFs can be derived from the E12.5 Atm-/-
Brca1tr/tr embryo which show slightly slower growth than Brca1tr/+ or Atm-/- 
counterparts. The comparison between embryos and newborn pups suggests the 
compound defects may be affecting the late embryonic stage. 
D. Examining HDR in Atm-Brca1tr primary ear fibroblasts carrying the DR-
GFP/inducible I-SceI system. The Brca1tr/tr ear fibroblasts show a moderate ~1.4-fold 
reduction in HDR (n≥3 except n=2 for WT;). However, HDR is severely reduced by 
~10-fold in Atm-/-Brca1tr/tr fibroblasts (n=1, site loss 22%) compared to WT cells. % 
HDR: % GFP+ normalized to % I-SceI site loss. All mice are from the Atm-Brca1tr 
colony. * Brca1+/+ or tr/+  
E. Treatment with ATMi (3 µM) in Brca1tr/tr ear fibroblasts inhibits HDR to a greater 
extent than in control cells (2- versus 1.6-fold reduction), though not as much as the 
extent of reduction (4-fold) in Brca1SF/SF cells (n≥3). These results suggest that HDR 
in the Brca1tr mutant may also have some dependence on ATM, but not to the similar 
level as the Brca1SF allele. The fold is relative to the % GFP+ of DMSO treatment of 
each animal. The dataset consists of mice from Brca1SF and Brca1tr colonies. 
F. Cell cycle profiles of Atm-/-Brca1tr/tr tail fibroblasts are similar to WT cells.  
G. Brca1tr/tr primary MEFs show an ~4-fold reduction in HDR. * Atm+/+ or +/- (n≥3) 
H. In Brca1tr/tr primary MEFs, treatment with ATMi does not reduce HDR to a greater 
extent than in WT MEFs, unlike the phenotype in Brca1SF MEFs (Chapter 2). One 
possibility could be that the HDR defect of Brca1tr allele is less severe than the 
Brca1SF allele that mitigates the requirement for ATM in MEFs. This may be related 
to the observation that Brca1tr ear fibroblasts also have smaller HDR reduction than 
Brca1SF upon ATM inhibition (see above). In addition, ATM deficiency has less 
pronounced effects on HDR in embryonic cells (Chapter 2). * Atm+/+ or +/- (n≥3) 
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Figure A.2 
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Figure A.2 (Continued) 
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Figure A.3 I-SceI transfection experiments in Atm mutant primary cells.  
(Part of which is published in Kass et al., PNAS, 2013) 
A. The kinase domain of ATM (residues 2722-2972, UniProt, www.uniprot.org) is 
encoded by exons 56-63 (Ensemble, useast.ensembl.org). The Atmb allele (Xu and 
Baltimore, 1996) contains a deletion of a portion of the kinase-encoding domain (exon 
59 and part of exon 60; deleting residues 2816-2875). The Atmw allele (Barlow et al., 
1996) contains a NeoR inserted in a reversed orientation that replaces exon 37. All Atm 
mutant experiments in the thesis are performed with the Atmb allele, except in Chapter 
2 Figure 2.5G where the Atmw allele is used. 
 To analyze the transcripts of the two Atm mutant alleles, reverse transcription 
is performed using RNA prepared from ear fibroblasts from WT, Atmw/w, and Atmb/b 
mice (Kass et al., 2013; w/w or b/b indicates homozygous mutant). PCR is performed 
on the prepared cDNA with three different primer sets to amplify exons upstream of 
the targeted mutations (exons 13-16; serve as a control) and at the site of the targeted 
mutations. The exons 13-16 product is detected from both Atmw/w and Atmb/b mice but 
at reduced levels, suggesting unstable mutant transcripts. The normal exons 34-42 
product is observed for Atmb/b mice at reduced levels but absent from Atmw/w mice; 
instead, Atmw/w mice have a lower level of an alternatively spliced product (denoted 
with asterisk). Sequencing of cloned PCR products indicates that it corresponds to a 
splicing event from exon 36 to exon 38 that skips the NeoR cassette (18 sequences 
analyzed by TOPO cloning), resulting in frameshift and truncation of ATM after 
residue 1838. The normal exons 54-62 product, encoding the kinase domain, is present 
at low levels in Atmw/w mice but absent from Atmb/b mice.  
B. A former lab member, Hildur Helgadottir, performed HDR analysis in the Atmw 
mutant by transfecting an I-SceI expression plasmid (pCBASce) in Atmw/w fibroblasts 
carrying the DR-GFP reporter but did not observe a significant HDR reduction (Kass 
et al., 2013). A similar experiment is performed in the Atmb mutant carrying the DR-
GFP reporter. Primary ear fibroblasts harvested from WT or Atmb/b mice are cultured 
to passage 3 to obtain enough cells for electroporation with the pCBASce plasmid 
(350 V / 950 µF; 3×106 cells with 30 µg plasmid). GFP-positive cells are analyzed 48 
hr after electroporation. The graphs presented here are the means of three experiments 
included in the Kass 2013 paper (bottom tables, experiments 1-3) and three additional 
ones; error bars indicate one standard deviation from the mean.  
The overall % GFP+ is low (0.4-0.6%) following pCBASce transfection in 
primary fibroblasts. Similar to the Atmw mutant, HDR in Atmb/b ear fibroblasts is not 
significantly different from WT cells in this assay (upper left, p=0.33). However, a 
trend of ~1.4-fold reduction in Atmb/b fibroblasts can be noticed (n=6). The 
transfection efficiency, as examined by an independent electroporation of an NZ-
EGFP plasmid, is ~25% for both genotypes (upper right). In comparison, the 
tetracycline-inducible I-SceI system has much higher efficiency (Kass et al., 2016; 
Chapter 2): Induction of I-SceI by doxycycline treatment can achieve ~50% DSB 
efficiency (as determined by site loss assay) and give rise to ~10% GFP-positive cells 
in WT fibroblasts. Thus, we think the robustness of the inducible I-SceI system allows 
for a better delineation of the modest HDR reduction in Atm-null primary cells 
compared to the transfection-based method.  
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C. Treatment with an ATMi KU-55933 reduces HDR in WT ear fibroblasts following 
pCBASce transfection, whereas HDR in Atmb/b fibroblasts is not affected by ATMi 
(n=5). The ~1.7-fold reduction in HDR in WT cells treated with 3 µM ATMi is similar 
to reduction fold in the inducible I-SceI system undergoing the same treatment 
(Chapter 2). The fold is relative to the % GFP+ of DMSO treatment. 
D.-E. The expression of ATM protein and the DNA damage response in primary ear 
fibroblasts from Atmw/w and Atmb/b mice are examined by western blotting in D and E, 
respectively. Atm mutant fibroblasts from both mouse strains do not have detectable 
ATM protein expression using an antibody against the C terminus of ATM (Abcam 
2C1, epitope human residues 2577-3056). Whereas WT fibroblasts display 
phosphorylation of ATM-targeted substrates (CHK2 and p53) following irradiation 
that can be abolished by ATMi treatment, both Atm mutant fibroblasts do not show 
visible phosphorylation events. 
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Figure A.3 (Continued) 
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Figure A.4 Effects of HDAC inhibition on HDR in ES cells.  
A. Given that ATM has a role in transcriptional silencing in the vicinity of DSBs 
(Shanbhag et al., 2010) and heterochromatin-associated repair (Goodarzi et al., 2008), 
we examine how chromatin perturbation influences HDR in ATM-deficient ES cells 
by treatment with a pan HDAC inhibitor Trichostatin A (TSA) that promotes 
chromatin relaxation.  
In DMSO-treated condition, HDR in Atm-/- ES cells is ~1.7-fold lower than 
WT at 24 hr after transfection of an I-SceI expressing plasmid pCBASce (p<0.05), 
however the difference is not observed at 48 hr, which we refer to in Chapter 2 as a 
delayed HDR in Atm-/- ES cells (top panel). Treatment with TSA (5/10 nM) 
significantly increases HDR in both cells lines, but the extent of increase is higher in 
WT than Atm-/- cells, such that a difference in 48-hr HDR can now be observed 
showing that TSA-treated WT cells have ~2-fold higher HDR than Atm-/- cells 
(p<0.01). This implies that the status of repressive chromatin may contribute to the 
diminished difference in HDR between WT and Atm-/- ES cells at later time points of 
repair. (n=3) 
The similar increase in % NZ-EGFP in both WT and Atm-/- ES cells suggests 
that the protein expression from transfected plasmids is not differentially altered by 
inhibition of HDAC (bottom panel).  
B. Analysis of site loss assay in ES cells (see Chapter 2 methods). Although % I-SceI 
site loss is low in pCBASce transfection experiments (compared with empty vector 
pCAGGS), it is increased by TSA treatment similarly in both WT and Atm-/- ES cells, 
suggesting no difference in overall repair between the two genotypes after HDAC 
inhibition (n=3). This also suggests that factors other than DSB efficiency contribute 
to the distinct change in HDR between WT and Atm-/- cells. For example, there may be 
more utilization of HDR versus NHEJ, increased DNA mobility, or less local silencing 
effects following TSA-induced chromatin relaxation in WT cells, and the activity of 
ATM is involved in these processes, leading to a difference between WT and Atm-/- 
cells.   
C. % HDR (i.e., % GFP+ normalized to % I-SceI site loss) of WT and Atm-/- ES cells 
treated with TSA shows similar trend as the analysis of % GFP+ shown above. 
D. We examine the effects of TSA in other cell types and find that treatment with TSA 
(10 nM, 48 hr) does not have a significant effect on HDR in primary ear fibroblasts 
carrying the inducible I-SceI system (n=4); however, a small increase in HDR can be 
seen in the immortalized WT MEFs (n=2). This suggests that the effects of TSA on 
HDR in ES cells may be context-dependent, e.g., in embryonic cells.  
E. Given that acetylation by Tip60 following chromatin perturbation contributes to 
ATM activation (Kaidi and Jackson, 2013), we analyze if TSA affects ATM activity 
but do not observe significant changes in ATM-dependent DNA damage signaling in 
irradiated WT ES cells pretreated with TSA. However, this could be re-examined with 
lower dose of IR to better visualize any phosphorylation change on ATM substrates. 
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F. Given that DNA-PKcs activity contributes to NHEJ and also to break-induced 
transcriptional silencing (Pankotai et al., 2012), we examine how DNA-PKcs 
inhibition affects HDR in ES cells. Treatment with a DNA-PKcs inhibitor NU-7441 (3 
µM) promotes a ~1.6- and 2-fold increase in HDR in WT cells at 24 and 48 hr, 
respectively, whereas the increase is ~1.2-fold in Atm-/- ES cells. This leads to a 
difference at 48 hr between the two genotypes such that HDR in WT is ~1.5-fold 
higher than Atm-/- cells. Whether this is related to the loss of NHEJ competition or 
chromatin silencing needs to be further examined. (n=3) 
 
Summary of HDAC and DNA-PKcs inhibitor experiments:  
We propose in the discussion of Chapter 2 that alternative mechanisms, such as ATR 
and EXO1, compensate for the delayed HDR in Atm-/- ES cells (see Appendix Figures 
A.5 and A.6). However, a different possibility is that some phenotypes change in the 
context of WT rather than Atm-/- cells, creating the difference between the two cell 
lines. 
Here, we hypothesize that the chromatin conformation around the break site 
may change after DSBs in WT ES cells and become more compact. This somehow 
alters pathway utilization towards more NHEJ at later time points (similar to the 
context of heterochromatin) and thus a diminished difference between WT and Atm-/- 
ES cells at 48 hr. Such NHEJ usage can be suppressed by DNA-PKcs inhibition to 
promote ATM-mediated HDR in WT cells at 48 hr. Treatment of TSA relaxes the 
chromatin and thus also promotes HDR utilization in WT cells at 48 hr. It is unclear if 
the process of repressive chromatin formation, if any, is entirely ATM-dependent or 
partially, since TSA treatment also increases HDR in Atm-/- ES cells (albeit not as 
much as in WT). The molecular mechanisms of TSA-induced effects on chromatin 
and HDR remain to be elucidated. 
  Alternatively, a possibility is that TSA simply activates more ATM in WT 
cells causing higher HDR, however we do not see an increase in ATM signaling by 
TSA treatment in the preliminary western blot results. Furthermore, this is more 
difficult to explain the delayed HDR response in Atm-/- versus WT cells between 24 
and 48 hr, i.e., why ATM is less activated in WT at 48 hr if this is the case. 
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Figure A.4  
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Figure A.5 Effects of ATR kinase inhibition on HDR. 
(Part of which is published in Vriend et al., NAR, 2016) 
A. Because ATR kinase can promote end resection independently of ATM in the 
EXO1-proficient condition (Peterson et al., 2013), we examine how inhibition of ATR 
affects HDR. Treatment with an ATR kinase inhibitor VE-821 (1 µM) suppresses 
HDR by ~1.4-fold in WT ES cells, suggesting ATR activity plays a role in HDR. ATR 
inhibition in Atm-/- ES cells also causes a similar ~1.4-fold reduction in HDR, 
suggesting ATR still contributes to HDR even in the absence of ATM. Despite the 
similar fold of HDR reduction, whether ATR promotes HDR through the same 
mechanism in WT and Atm-/- cells needs to be further examined. (n=3) 
B. Treatment with 1 µM ATRi slightly increases the S-phase population of ES cells at 
24 hr (p<0.01 for WT but not significant for Atm-/-). At a higher dose of 3 µM, cells 
start to show S-phase accumulation and cannot be consistently plotted by the FlowJo 
cell cycle analysis tool; examples of population distribution are shown in the right 
panel. (n=4) 
C. Treatment with hydroxyurea (HU) induces replication stress by depleting 
nucleotide pools. This leads to ATR activation in WT ES cells and phosphorylation of 
its substrate CHK1 on S345 (equivalent to human S345), which can be ablated by 
treatment with an ATR inhibitor. On the other hand, ATR inhibition increases CHK2 
phosphorylation (indicated by the mobility shift) in response to HU, which is likely an 
indication of DSB accumulation due to the blockade of S-phase repair by ATRi 
treatment. 
D. ATR inhibition does not affect CHK2 phosphorylation in response to IR, which is 
predominantly phosphorylated by ATM. 
E.-F. Given that treatment with ATRi or ATMi inhibits HDR in human U2OS cells 
(Vriend et al., 2016), we confirm that these inhibitors are effectively suppressing the 
corresponding DNA damage signaling pathways in this cell line. In E, ATRi treatment 
blocks the phosphorylation of ATR substrate CHK1 on S345 in a dose-dependent 
manner upon HU-induced replication stress. ATR inhibition also leads to increased 
DSB formation particularly in the HU-treated condition as indicated by the increased 
autophosphorylation of ATM on S1981. This is similar to the increased CHK2 
phosphorylation in mouse ES cells described above. In F, ATMi treatment blocks 
ATM-mediated phosphorylation on its substrate CHK2 and KAP1 in a dose-dependent 
manner following IR. 
Primary antibodies are diluted in 2.5% milk as listed below: Anti-CHK1 
pS345, 1:750 (Cell Signaling #2341); Anti-CHK1, 1:750 (Santa Cruz sc-8408); Anti-
ATM pS1981, 1:2000 (Rockland 200-301-400); Anti-CHK2 pT68, 1:1000 (Cell 
Signaling #2661). 
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Figure A.5 (Continued) 
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Figure A.6 The role of EXO1 in HDR between diverged sequences.  
(Part of which is published in Chen et al., DNA Repair, 2017) 
A. EXO1 is a 5’ to 3’ exonuclease that functions in the mismatch match repair with 
the MutSα complex (MSH2-MSH6) and also in the extensive step of end resection of 
DSB repair. We examine how loss of EXO1 affects HDR in Exo1-/- mouse ES cells 
integrated with the DR-GFP reporter (see Figure A.7C for Southern blots of these 
clones). The average levels of HDR of two Exo1-/- DR-GFP clones do not have 
significant difference compared to that of WT J1 ES cells at 24 and 48 hr after 
pCBASce transfection (left and middle panels). HDR of individual clones show a 
similar trend (right). These results suggest that EXO1 loss generally does not impair 
HDR following I-SceI-induced DSBs, possibly due to the redundancy of resection 
machinery or the length of resection tract required for revealing homology. 
B. ATM inhibition (3 µM) reduces HDR by ~1.5-fold in both WT and Exo1-/- DR-
GFP ES ells at 24 hr. Interestingly, at 48 hr, HDR in WT cells shows a less 
pronounced response to ATM inhibition, whereas HDR in Exo1-/- cells is still reduced 
by ~1.4-fold (n≥5). The smaller extent of HDR reduction at 48 hr is not due to loss of 
effect of the inhibitor, as the inhibitor-containing medium is replenished every 24 hr; a 
more frequent change of the inhibitor (every 4-6 hr) in WT cells also yields similar 
results (not shown). One interpretation is that the smaller effects of ATMi at 48 hr in 
WT ES cells is analogous to the delayed HDR response observed in Atm-/- ES cells 
(Chapter 2). Given that EXO1 is able to compensate for the resection of clean DSBs 
upon ATM deficiency (Peterson et al., 2013), it may be acting as an alternative 
resection pathway to support HDR at later time points. Thus, ATM inhibition in 
EXO1-deficient cells leads to more persistent HDR suppression compared to EXO1-
proficient cells. This hypothesis can be further examined by depleting the redundant 
resection factors in ATM-deficient cells. 
C. To examine how the mismatch repair function of EXO1 influences HDR between 
diverged sequences, Jeannine LaRocque in the lab modified the DR-GFP reporter to 
carry 11 silent mutations in the iGFP gene (i.e., DR-GFP-11mu; 1.4% increase in 
divergence; see top diagram) that cause mismatch with the SceGFP sequence during 
homologous pairing (Chen et al., 2017). 3.5×106 parental Exo1-/- ES cells are 
electroporated (225 V / 950 µF) with 16 µg of DR-GFP original (denoted by +) or 
11mu plasmid together with 16 µg each of pCBASce and/or pCAGGS-mouse EXO1 
expression plasmid and analyzed for HDR at 48 hr. In Exo1-/- cells complemented with 
the EXO1 WT protein, HDR between diverged sequences is suppressed by 10-fold 
compared to that between identical sequences (compare DR-GFP 11mu versus +; % 
GFP+ in left panel, relative fold in right panel). In Exo1-/- cells transfected with an 
empty vector or a nuclease-inactive D173A mutant (Shao et al., 2014), HDR between 
diverged sequences is both reduced by only ~1.6-fold. These results suggest that 
EXO1 inhibits recombination between diverged sequences in a manner dependent on 
its nuclease activity. The small 1.6-fold reduction in HDR between diverged 
sequences in the absence of EXO1 also suggests that other mismatch repair factors can 
still contribute to heteroduplex rejection. (n=3) 
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 The pCAGGS-mouse EXO1 D173A plasmid is provided by Winfried 
Edelmann at Albert Einstein College of Medicine and the point mutation is confirmed 
by sequencing (GAC to GCC). 
D. Western blots confirm the expression of EXO1 WT and D173A protein in Exo1-/- 
parental cells at the 48-hr time point of flow cytometry. Expression levels from 
transfected plasmids are typically much lower at 48 hr than 24 hr in ES cells (see 
below), thus only a faint band of EXO1 protein is detected in the blot (arrow). 
Expression of the HA-tagged I-SceI is similar among all pCBASce-transfected Exo1-/- 
cells. 
 Primary antibodies used: Anti-EXO1, 1:1000 in 5% BSA (Bethyl Laboratories 
A302-640A); Anti-HA, 1:1000 in 2.5% milk (Convance MMS-101P). 
E. Western blots of a different EXO1 complementation condition. 5×106 Exo1-/- DR-
GFP cells are electroporated (230 V / 950 µF) with 20 µg of pCBASce and 20 µg of 
pCAGGS-mouse EXO1 WT or empty vector. Lysates are collected at 24- and 48-hr 
time points of flow cytometry. The expression of EXO1 protein in complemented 
Exo1-/- cells is comparable to the endogenous level in WT J1 cells at 24 hr but 
becomes much lower at 48 hr. A similar 24-48 hr difference is observed for the I-SceI 
expression. 
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Figure A.6 (Continued) 
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Figure A.7 Southern blots of J1, Atm-/-, and Exo1-/- DR-GFP clones.  
A.-C. WT J1, Atm-/- (Xu et al., 1996), and Exo1-/- (Schaetzlein et al., 2013) ES cell 
lines are integrated with a DR-GFP reporter to the Pim1 locus using a gene trapping 
method described previously (Moynahan et al., 2001). 1-2×107 ES cells are transfected 
with 75 µg linealized p59xDR-GFP6 plasmid (XhoI digestion for 7 hr and gel-
purified), electroporated at 250 V / 950 µF, and plated to 2-3 10-cm dishes. After 48 
hr, the cells are double-selected in 110 µg/ml hygromycin and 1 µg/ml puromycin for 
~10 days and the resistant colonies are isolated for genomic DNA purification using 
Gentra Puregene Tail kit. 5 µg genomic DNA is digested in 20 U HincII (30 µl total 
volume) for 7 hr, and the reaction is replenished with additional 5 U HincII for 
overnight digestion. The digested DNA is separated on a 0.8% long gel at 120 V for 6 
hr and transferred to a nylon membrane (GeneScreen Plus) in the alkaline buffer 
overnight. To prepare the Pim1 probe template, the p22 probe plasmid is first digested 
in BstXI overnight (10 µg plasmid × 3 reactions) and separated on a 0.8% gel. The 
1.7-kb fragment is purified and digested again in HincII overnight (2.2 µg eluted DNA 
× 3 reactions). After separating on a 0.8% gel, the 1.1-kb fragment is eluted in TE 
buffer (61 ng/µl × 30 µl total). The probe is synthesized using Prime-It II Random 
Primer Labeling Kit with 240 ng template and α-32P-dATP and then used for 
membrane hybridization at 65°C overnight following standard protocols (Pierce and 
Jasin, 2005). A DR-GFP-targeted allele shows a 2.4-kb band for this probe, whereas 
the endogenous Pim1 allele is 3.6 kb.  
The results of Southern blotting and EtBr-stained gel images for WT J1, Atm-/-, 
and Exo1-/- cells are shown in A, B, and C, respectively. Note that in A, the genomic 
DNA of parental J1 control is lost and thus does not show up on the Southern blot 
(blue asterisk). This has been repeated in the following experiments shown in B. A 
WT ES cell line carrying a Pim1Drgfp allele previously established in the lab 
(Moynahan et al., 2001) is used as a positive control. The J1 clones 1/3/8 and Atm-/- 
clones 1/3/4 are used for HDR analysis in Chapter 2, Figure 2.1. The Exo1-/- clones 2 
and 6 are analyzed in Appendix Figure A.6. 
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Figure A.7 (Continued) 
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Figure A.8 Construction of 53bp1 mutant ES cell lines. 
A.-C. 53bp1 single mutant.  
A. To mutate the 53bp1 gene, we follow a previously described method in the lab 
(Zhang et al., 2014). As shown in the scheme, CRISPR/Cas9 is used to introduce a 
DSB into exon 2 of 53bp1 to facilitate the replacement of exon 2 with an in-frame 
resistance cassette (NeoR is depicted here) via homologous recombination, leading to 
the disruption of the 53bp1 reading frame. All resistant clones are first screened by 
PCR amplification across the targeted exon 2 using primers internal to the homology 
arms (red forward/red reverse), labeled as internal PCR on the scheme. This primer set 
cannot distinguish targeted versus random integrations, but has robust efficiency to 
facilitate the screening process. A NeoR targeting event (or random integration) will 
produce a ~1.6-kb band in this internal PCR, whereas the WT band is 0.5 kb. 
 PCR results are analyzed with stringent criteria: Thus, even though many 
clones show a faint band at the 1.6-kb position that could represent successful 
targeting of the Neo gene (asterisk, below) together with a stronger 0.5-kb WT band 
(e.g., #64), they are not further pursued. (Note: Amplification efficiency of the much 
smaller fragment is significantly better.) Only the clones that show potential biallelic 
modifications, i.e., with the predicted pattern of cassette integration (~1.6 kb) in 
conjunction with loss of the WT exon 2 band (0.5 kb) or distinguishable shifts to this 
band, indicating insertions/deletions on the endogenous allele, are further 
characterized. The second PCR analysis, labeled as In-Out PCR on the scheme, uses 
primers amplifying from intron 1 (red forward, which anneals to either the 5’ 
homology arm or the endogenous locus) to intron 4 (green reverse, anneals to the 
endogenous locus only) of 53bp1 to identify correct integration of the template. A 
correct NeoR integration will produce a ~2.3-kb band in the In-Out PCR, whereas the 
WT band is 1.2 kb. The selected clones are then analyzed by western blotting to 
determine the expression of the 53BP1 protein. The derivative clones that have lost 
53BP1 expression are referred to below and in the main texts as 53bp1-/-. 
B. 53bp1 targeting is performed in WT J1 ES cells with a NeoR template because of a 
HygR marker at the Pim1Drgfp locus of this cell line. Among the 94 resistant clones 
analyzed by internal PCR, 11 clones potentially have bi-allelic modifications (all of 
them show a single band shifted from the 0.5-kb WT position likely due to insertions, 
e.g., #26 and #55, or deletions, e.g., #36 and #66). Three clones show mono-allelic 
modification together with a WT band, e.g. #42 (insertion) and #45 (deletion). Two 
clones do not have an amplified exon 2 band but have a faint band at 1.6 kb, i.e., #31 
and #53. Many clones show a faint upper band together with a WT band but this 
internal PCR cannot tell if it is mono-allelic targeting or random integration, e.g. #27 
and #64. 
 Further analysis using the In-Out PCR suggests that #26 has a potentially 
targeted allele and another allele with insertions. #66 has a potentially targeted allele 
and another allele with deletions. #42 has a WT allele and insertions on the other 
allele. Clones from targeted Brca1ex11 cells are used as positive and negative controls 
here.  
C. Nine 53bp1-targeted J1 clones are examined for 53BP1 expression. #26 shows the 
absence of 53BP1 band (blue arrow), whose position is determined based on 53bp1-/- 
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primary cells in other experiments (see A.6E below). #31 retains the full-length 53BP1 
band along with a smaller band slightly above 268 kDa, which can also be seen in the 
remaining clones. Clone #26 was selected as the 53bp1-/- single mutant (i.e., Brca1+/+) 
for further analysis (Figure 3.2). 
D.-E. Brca1ex11/ex11 53bp1 double mutant.  
D. 53bp1 targeting is performed in a derivative clone (#3) of Brca1ex11/ex11 ES cells in 
which the existing HygR gene was previously disrupted by Cas9. Thus, a HygR 
template could be used for this targeting. Among the 161 resistant clones analyzed by 
internal PCR, 14 clones potentially have bi-allelic modifications (#17, #18, and #62 
show a single band between 1-1.7 kb and no 0.5-kb WT band; the remaining show a 
band shifted from the 0.5-kb position, e.g., #95 and #100). One clone, #22, potentially 
has mono-allelic targeting together with a WT band. Four clones do not have 
amplified products, e.g., #31 and #40. Some clones may have cassette integration on a 
single allele, but it is difficult to conclude due to the faint upper band, e.g., #30. 
Further analysis using the In-Out PCR suggests that #17 and #18 have 
potential cassette integration on one or both alleles (though the upper band is slightly 
lower than the predicted ~2.3 kb); it is also possible that one allele has modification 
beyond the red forward primer binding site. Clone #22 has a potentially targeted allele 
(marked by the green asterisk) and a WT allele.  
E. Seven 53bp1-targeted Brca1ex11/ex11 clones are examined for 53BP1 expression. All 
of them, except #22, show the absence of 53BP1 band (blue arrow). #22 has a faint 
band at the full-length 53BP1 position after longer exposure, suggesting it may be a 
53bp1 heterozygous or mixed clone. The 53bp1-/- control is derived from primary 
mouse fibroblasts. Clones #17 and #18 were selected as Brca1ex11/ex1153bp1-/- double 
mutants for further analysis (Figure 3.3). 
F.-G. Brca1SF/SF 53bp1 double mutant.  
F. 53bp1 targeting is performed in Brca1SF/SF ES cells using a HygR template. Among 
the 64 resistant clones analyzed by internal PCR, 7 clones potentially have bi-allelic 
modifications (#35, #37, and #41 show a single band ~1.7 kb and no 0.5-kb WT band; 
the rest of them show a band shifted from the 0.5-kb position, e.g. #39). One clone, 
#13 (see below), has mono-allelic targeting together with a WT band. Two clones do 
not have amplified products, e.g. #30.  
Further analysis on a few clones using the In-Out PCR suggests that #35, #37, 
and #41 have potential targeting either on both alleles (maybe #41 due to stronger 
band intensity) or on one allele in conjunction with loss of primer-binding site on the 
other allele. #25 may have insertions either on both alleles or on one allele together 
with loss of primer-binding site on the other allele. #33 has a potentially targeted allele 
and another allele with insertions. #13 has a WT allele and another allele with 
insertions. 
G. Nine 53bp1-targeted Brca1SF/SF clones are examined for 53BP1 expression and 5 of 
them showed absence of the 53BP1 protein (blue arrow). The Brca1SF/SF53bp1-/- #25 
and #37 have the cleanest background in the blot (i.e., without the faint band at the 
bottom) and are selected for HDR analysis (Figure 3.3). #13 may be a 53bp1 
heterozygous clone. #39 has full-length 53BP1 protein band but may still have in-
frame small deletions due to the shift in internal PCR.  
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Figure A.8 
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Figure A.8 (Continued) 
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Figure A.9 Supporting data of Brca1SF and Brca1ex11 mutant ES cells. 
A. BRCA1SF protein is expressed at a lower level than WT BRCA1 in ES cells, likely 
due to the folding defect of BRCT domain mutation, however it can be transiently 
stabilized by treatment with a proteasome inhibitor MG-132 for 6 hr. Anti-BRCA1: 
dilution 1:500 in 5% BSA overnight (o/n), monoclonal against mouse BRCA1 amino 
acids 160-300 (provided by Samuel Bunting at Rutgers University). 
B. Phosphorylation of CtIP by ATM, as indicated by the mobility shift, following 20 
Gy IR shows similar patterns between WT, Brca1SF/SF, and Brca1ex11/ex11 ES cells and 
is not observed in Atm-/- cells. Anti-CtIP: dilution 1:250 in 5% BSA o/n (provided by 
Richard Baer at Columbia University) 
C. The 53BP1 protein in Brca1ex11/ex11 ES cells shows a more prominent mobility shift 
than in Brca1SF/SF cells following olaparib treatment for 20 hr. ATM inhibition can 
attenuate but not completely abolish the shift of 53BP1. This suggests that ATM may 
be inducing higher levels of 53BP1 phosphorylation in the Brca1ex11 mutant, but more 
molecular characterization is needed. Anti-53BP1: dilution 1:4000 in 2.5% milk 
(Novus NB100-304); 7.5% Tris-Gly gel transferred at 22 V o/n. 
D.-G. Analyzing chromatin association of 53BP1  
D. Inhibition of ATM appears to increase the levels of chromatin-bound 53BP1 
particularly in olaparib-treated Brca1SF/SF cells, suggesting ATM may have a role in 
counteracting the localization of 53BP1 to DNA upon damage in the Brca1SF mutant. 
See below for quantification. It is interesting to note that CtIP binding to chromatin 
also increases in the olaparib-treated Brca1SF mutant and shows a slightly shifted 
pattern not suppressed by ATMi, but it is unclear if this means that the cells attempt to 
perform resection/HDR or if CtIP is blocked at the DSB sites from dissociation; in 
total cell lysates, the IR-induced shift of CtIP is similar between the two Brca1 
mutants (see Figure A.9B above).  
The ES cells are treated with olaparib (0.5 µM) with or without ATMi (5 µM) 
for 20 hours. Cells are trypsinized and 2×106 cells were fractionated using Thermo 
Fisher Subcellular Protein Fractionation Kit to isolate chromatin-bound proteins for 
western blot. The blots are quantified using ImageJ. The band intensity of 53BP1 is 
normalized to that of internal control HDAC2 first and then compared between the 
two Brca1 mutants on the same blot for each experiment. Three out of five 
experiments are shown here. 
E. In the condition with olaparib treatment, combination with ATMi in Brca1SF/SF ES 
cells leads to a significant increase in chromatin-bound 53BP1 compared to olaparib 
alone. Such change is not evident in the Brca1ex11/ex11 or WT cells. The fold is relative 
to the sample treated with olaparib alone in each genotype. (n=5 except n=1 for WT) 
F. In the undamaged condition, Brca1ex11/ex11 cells show slightly higher levels of 
chromatin-bound 53BP1 than Brca1SF/SF cells, perhaps related to its more severe HDR 
defect at baseline level. The fold is relative to the Brca1SF/SF sample treated with only 
DMSO. (n=5) 
G. The BRCAΔ11 protein can be found localized to the chromatin (more obvious with 
olaparib treatment), whereas the BRCASF protein is not very observable in part due to 
the instability of BRCT mutant peptide. Two experiments are shown here. Anti-
BRCA1: 1:1000 in 5% BSA o/n (Santa Cruz H-100). 
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Figure A.9 (Continued) 
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Figure A.9 (Continued) 
 
